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Abstract and Key Words 
 
This thesis details the development of a novel cobalt catalyst for the Mukaiyama 
oxidative cyclization of THF (tetrahydrofuran) rings.  The Mukaiyama cyclization has been 
an effective methodology for the formation of trans-THF rings and has been utilized in the 
synthesis of several natural products.  The first Chapter in this document outlines the 
development of a water soluble Co(nmp)2 catalyst and its improved performance in the 
Mukaiyama cyclization. 
 The second chapter details further applications of the Co(nmp)2 catalyst.  These 
applications include failed attempts at alkyne cyclizations and the successful application to 
trisubstituted 2,2,5-THF products.  Applications of Co(nmp)2 in total synthesis and 
synthetic methodology are also discussed.  
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1. The Synthesis of Tetrahydrofuran Derivatives  
 
 
 Tetrahydrofuran (THF) ring systems have attracted considerable attention as 
synthetic targets due to their prevalence in naturally occurring molecules demonstrating 
significant biological activity.1 The discovery of a new class of polyketide natural products, 
known as acetogenins, derived from plants in the Annonaceae family, in recent years has 
only served to strengthen the field of study.2  These and many other compounds containing 
THF ring structures are often part of fused and/or macrocyclic ring systems.  THF natural 
product’s potent bioactivity has been shown to produce potential anti-cancer properties. To 
explore these properties for pharmaceutical application, it is necessary to produce the 
molecules on a large scale.  As a direct result of the need for large scale synthesis of THF 
rings and natural products, many innovative methods have been developed to facilitate 
their synthesis. These methods use a diverse array of strategies, which include radical 
cyclization,3 chlorohydrin displacement,4 donor-acceptor cyclopropane annulations5 and 
many others.6 
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1.1 SN2 THF Cyclization Methods 
 
1.1.0 General mechanism 
 
 A THF ring is a cyclic 5-membered ether and the C – O bond of this structure is the 
predominant retrosynthetic disconnection.  There are various ways in which the C – O bond 
can be formed but the most straightforward is an SN2 reaction between an alcohol and a 
leaving group.  As a fundamental reaction in organic chemistry, the Williamson ether 
synthesis provides a simple illustration of THF synthesis via an SN2 pathway.7  Alcohol 
1.01 can be treated with base to form an alkoxide species.  This can undergo backside 
attack displacing the bromide leaving group.  This is a clean and simple illustration of how 
an SN2 pathway would proceed but in actual application it can produce side products 
through an elimination pathway.  Several methods have been developed to avoid the 
elimination product. 
 
Scheme 1. Williamson Ether Synthesis 
 
1.1.1 Chlorohydrin cyclization 
 
The Britton group has applied chlorohydrin cyclization to the formation of THF 
rings and have adapted it to oxygenated THF rings (Scheme 2). 4  The ability to control and 
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modify the stereochemical outcome of this reaction makes this methodology very 
interesting.  Various reaction conditions can be applied to a single starting material to 
access all of the possible stereoisomers of the product THF.  These modes of reactivity 
include epoxide formation and opening, direct cyclization and Lewis acid mediated 
cyclization.  These reactions occur in good yield and with diastereomeric ratios (dr) up to 
20 :1.  This strategy is very robust and is limited only by the synthesis of the starting 
material. 
Synthesis of the THF products can be achieved via treatment of chlorodiol 1.05 with KOH 
in ethanol to afford epoxide 1.06 in 97% yield (Scheme 3).  Epoxide 1.06 can be treated 
with 10 mol % BF3·OEt2 in CH2Cl2 to afford THF 1.07 in 92% yield.  Chlorodiol 1.03 
reacted under the same conditions producing a 96% yield over 2 steps (Scheme 2).  The 
epoxide intermediate allows for retention of stereoconfiguration at the chloride position 
into the THF product.  This occurs as the epoxide inverts the stereocentre and subsequent 
attack re-establishes the previous configuration. 
 
Scheme 2. Britton BF3 THF Synthesis 
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Scheme 3. Mechanism of Britton’s BF3 THF Synthesis 
 
 
Britton’s initial conditions allow for the synthesis of 4,5-trans THF products with both 2,5-
cis and trans relative diastereoselectivity based on the correct chlorodiol.  An alternative 
set of conditions were necessary to invert the stereochemistry of the 5 position in the THF 
product.  Britton found that AgOTf was able to coordinate the chloride and adjacent alcohol 
together to both activate the chloride position and discourage epoxide formation (Scheme 
4).  The conformation of the silver complex allowed for attack of the pendant alcohol and 
access to the desired 4,5-trans products.  The reaction required stoichiometric amounts of 
AgOTf and Ag2O, which were found to decrease decomposition, presumably by 
scavenging TfOH.  In addition to Britton’s original reaction conditions, it was found that 
microwave assisted transformations gave excellent yields of the dihydroxylated THF 
product (1.10, Scheme 5).4  
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Scheme 4. Silver Triflate Mediated transTHF Synthesis 
 
 
Scheme 5. Britton Chlorohydrin THF Synthesis 
 
1.1.2 Epoxide Opening Synthesis 
 Epoxide cascade reactions are an efficient method for forming several cyclic ethers 
in a single reaction pot.8  By strategically placing epoxide and alcohol moieties, many ring 
systems can cyclize under the same conditions.  Jamison and co-workers used this method 
to access tetrahydropyran (THP) moieties.   The Jamison method allows for a pendant 
alcohol to attack a single epoxide, creating a newly formed THP with an alcohol 
functionality (Scheme 6).  This alcohol can then undergo the same reaction and is 
propagated through several tethered epoxide centres. 
   
Scheme 6. Jamison Epoxide Cascades 
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 While the Jamison method selectively produces 6 membered rings, it is also 
possible to access multiple THF rings in a one-pot synthesis.  Hoye used an epoxide 
opening strategy for the bis-THF (+)-parviflorin.9   Diepoxide 1.14 was subjected to 
Sharpless asymmetric dihydroxylation conditions to provide the diol precursor for an 
“inside-out” epoxide opening cascade (Scheme 7).  Treatment with TFA afforded the THF 
product (1.15) in 85% yield over two steps. 
 
Scheme 7. Hoye bis-THF Synthesis 
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1.2 THF Formal Cycloaddition Methods 
1.2.0 Formal Cycloaddition General Mechanism 
 A cycloaddition is the addition of two unsaturated compounds to form a cyclic 
molecule with a lower bond order than the precursor and the reaction occurs in a concerted 
fashion.  A formal cycloaddition gives the cycloaddition product without a concerted 
reaction mechanism.  The general mechanism shown in Scheme 8 depicts a dipolarophile 
undergoing a nucleophilic attack to create zwitterionic intermediate II, which can then 
form the cycloadduct.  This concept has been explored in many unique transformations5,12 
and several will be discussed in further detail below. 
 
Scheme 8. General [3+2] Formal Cycloaddition Mechanism 
 
 
1.2.1 Johnson’s Donor-Acceptor Cyclopropane THF Synthesis 
 Donor-acceptor cyclopropanes have been adapted to form an extensive array of 
cycloaddition products arising from a wide array of dipolarophiles.10  The Johnson 
cyclopropane annulation with aldehydes can selectively give cisTHF products.  The 
addition of Sn(OTf)2 to cyclopropane 1.19 and an aldehyde gave near quantitative yields 
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for almost all examples.  The reaction shows excellent diastereoselectivity for larger R 
groups (Ph, iPr) and almost full retention of stereochemistry from the starting cyclopropane 
(Scheme 9).   
 
Scheme 9. Johnson Cyclopropane Annulation with Aldehydes 
Retention of the enantiomeric purity of the cyclopropane occurs through an SN2 attack of 
the chiral centre (Scheme 10).  After the initial attack, the zwitterionic species (Scheme 10, 
I) will rotate to allow attack of the aldehyde carbon by the malonate.  Bond rotation in 
intermediate I will force the molecule into a cis configuration as this puts both phenyl 
groups in the more stable equatorial positions in the final product (1.20a).    
 
Scheme 10. Johnson Annulation Mechanism 
 A unique variation on this reaction occurs with the use of a MgI2 Lewis acid and an 
equivalent amount of chiral ligand (Scheme 11).  These reaction conditions allow the use 
of a racemic cyclopropane (1.21) starting material, which is resolved to a highly 
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enantioenriched product (1.22).  Good yield and high diastereoselectivity are conserved 
from the previous Sn(OTf)2 catalyzed reactions.         
 
Scheme 11. Enantioselective Cyclopropane Annulation 
 Two major factors contribute to the enantioenriched product produced from a 
racemic mixture.  The first is background reactivity of the cyclopropane.  Magnesium 
iodide is able to open a donor-acceptor cyclopropane ring and subsequently reform the 
same compound (Scheme 12).  Given no preference to the reformation of a single 
enantiomer, the cyclopropane will always revert back to a 1:1 er of the starting material.  
Secondly, the chiral PyBOX (1.23) catalyst causes a dynamic kinetic resolution, resulting 
in excellent er of the THF products.  The addition of the PyBOX ligand causes a single 
enantiomer of the racemic mixture to react at a higher rate than the other.  These conditions 
are able to deplete one enantiomer of the starting material through selectively reacting with 
a single enantiomer and then converting the other to the kinetically favoured starting 
material. 
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Scheme 12. DyKAT (Dynamic Kinetic Asymmetric Transformation) Pathways for Aldehyde Cycloaddition 
1.2.2 Prins Cyclization 
  The Prins cyclization is an acid-catalyzed reaction producing a cyclic acetal 
from an aldehyde and alkene (Scheme 13).11  Activation of the aldehyde by acid catalyst 
allows for nucleophilic attack by the alkene moiety (I, Scheme 11).  This produces a 
carbocation intermediate (II) that can react through several pathways.  The excess aldehyde 
can react with intermediate II and form an acetal (1.31).  Water can terminate the reaction 
to form both the hydrated product (1.32) and the elimination product (1.33).  The hydration 
product is formed by direct attack of the carbocation by water.  The elimination product 
uses water as a base to cause β-elimination and give an allylic alcohol. 
11 
 
 
 
 
Scheme 13. General Prinz Cyclization 
 Panek and coworkers were able to use the carbocation intermediate of the Prins 
cyclization for the synthesis of THF rings.12  Their strategy begins with a BF3·OEt2 
catalyzed addition of a (E)-crotylsilane (1.34) into various aldehydes (Scheme 14).  
Transition state I produces the anti-product as the major diastereomer allowing for high 
diastereoselectivity in the final THF.  Where the Panek method differs from a standard 
Prins reaction is in quenching the carbocation intermediate II; by strategically placing a 
silyl group, which can stabilize the carbocation, they are able to “lock” the structural 
conformation of the molecule.  This unstable intermediate (III) can then be attacked by the 
newly formed alcohol to give the final THF product (1.35).  Panek’s method allows for the 
creation of three stereocentres and a THF ring in highly diastereoselective fashion. 
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Scheme 14. Panek THF Synthesis 
1.3 Radical Cyclizations of Substituted THF Rings 
 
 Radical reactions provide an efficient way to produce cyclic compounds and have 
been utilized in the production of THF rings.13  Radical cyclizations require an initiation 
step to form a radical species, and a classic initiator is AIBN (1.36), which under high 
temperature or light stimulus decomposes into two equivalents of isobutylnitrile radical (I) 
(Scheme 15).  This radical can then be transferred to Bu3SnH, which will go on to react 
with the cyclization substrate (II).  The tin radical selectively attacks halogen species 1.37 
to form a carbon radical on the substrate (III).  The radical then cyclizes forming the 5-
membered ring, as Baldwin’s rules favour 5-exo-tet over 6-endo-tet.  Finally, the resultant 
radical (IV) is quenched by Bu3SnH to form the product (1.38) and propagate the reaction.   
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Scheme 15. General Radical Cyclization Mechanism 
1.3.0 Carbon Centred Radical THF Cyclization 
 Carbon-centred radical cyclizations have been used to create THF compounds in 
natural product synthesis.14  The Kim group used a diethyl tartrate-derived cyclization 
precursors (1.39) to access bis-THF structures (Scheme 16).  When precursor 1.39 was 
submitted to radical cyclization conditions it afforded 81% of the desired product (1.40).  
Kim’s cyclization conditions produced the cis product exclusively and was extended to 
include the synthesis of THP rings. 
 
Scheme 16. Radical Mediated Synthesis of a bis-THF 
1.3.1 Sammis Oxygen Centred Radical Cyclization 
 Radical cyclizations have been applied in the synthesis of trans-THF rings.  The 
Sammis group has developed conditions for generation of an oxygen-centred radical that 
cyclizes onto strategically placed silyl enol ethers (Scheme 17).3  This reaction selectively 
forms the THF exo addition product over the endo-pyran, conforming to Baldwin’s rules.  
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These reaction conditions produce good yields with up to 9:1 diastereoselectivity (Scheme 
17).  Diastereoselectivity arises from transition state 1.43 as transition state 1.44 is 
disfavoured due to steric interactions of the silyl group (Figure 1).   Placing a sterically 
bulky group at R3 helps force the silyl enol ether into the desired transition state (1.43) 
improving dr (diasteromeric ratio). THF products with little substitution about the ring 
show a lower dr of 3:1 but maintain high yields.   
 
Scheme 17. Sammis’ Radical Cyclization 
 
 
Figure 1. Sammis’ Transition States 
 
1.4 Transition Metal Catalyzed THF Synthesis 
1.4.0 Cross Metathesis 
 Transition metal-catalyzed reactions have played a major role in expanding the 
scope of organic synthesis.  Many of these reactions have been applied to the formation of 
cyclic compounds including THF rings.  One such transition metal-catalyzed reaction is 
olefin metathesis – discovered by Zeigler15 in the 1950’s and made synthetically versatile 
by Grubbs in 1992 - it has become a staple in synthesis.16  Grubbs along with Schrock and 
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Chauvin were awarded the Nobel prize in chemistry in 2005 for their contributions in 
alkene metathesis.   Cross metathesis allows for the combination of various olefins to add 
substituents to an alkene effectively.  When used in the synthesis of cyclic molecules this 
process is referred to as ring closing metathesis (RCM).  Ring-closing metathesis requires 
the use of Mo or Ru complexes (1.47).17  These complexes are able to form a metallocycle 
(I) by cycloaddition to an alkene, which then eliminates a waste alkene and forms a carbene 
complex (II) (Scheme 19).  The carbene is now able to undergo an intramolecular 
formation of a carbocycle intermediate (III).  This intermediate can eliminate the catalyst 
to afford a DHF (dihydrofuran) product (1.46), which can be reduced under subsequent 
reaction conditions to afford a THF.  Grubbs demonstrated this reactivity using Schrock 
catalyst 1.47 at 5 mol % loading in benzene.18  Precursor  1.45 cyclizes selectively to the 
cis alkene due to ring constraint in good yield.  
O Ph
O
Ph
5 mol % 1.47
C6H6, 20 C
15 min
92%1.45 1.46
 
Scheme 18. Grubbs Ring Closing Metathesis 
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Scheme 19. RCM Mechanism 
1.4.1 Metal Catalyzed Trost Annulation 
 Palladium catalysis has been utilized by Trost to form THF rings with aldehydes.19  
Trost synthesized THF rings using allyl acetate with a pendant metal functionality (1.53) 
(Scheme 20).  The palladium catalyst undergoes oxidative addition to the allyl acetate 
forming a π-allyl complex (I) and the pendant tin species is removed, by nucleophilic attack 
of acetate, allowing the nucleophilic reactivity of the trimethylenemethane species (II).  
Aldehyde is added to the reaction mixture and is attacked by the nucleophilic 
trimethylenemethane leaving a newly formed alkoxide species, which undergoes 
cyclization with the π-allyl complex to form the exomethylene THF product (1.55).  Trost 
was able to form the desired THF product (1.51) in 73% yield when using aldehyde 1.50 
(Scheme 21).  
The stereochemical outcome of the Trost cyclization reaction is cis and the er is 
conserved from the nucleophilic alcohol (Scheme 22).  When the benzoate starting material 
1.56 is displaced by Pd0, it forms complex (I).  This transition state allows backside attack 
on the palladium complex to form the cis product.  Steric interactions of the oxygen centre 
17 
 
 
 
are cited as the predominant reason for the facial selectivity but further studies also 
incorporate 1,3 interactions as an integral factor in the resultant dr. 
 
 
Scheme 20. Trost Annulation Mechanism 
 
 
Scheme 21. Trost Annulation 
 
Scheme 20. Intramolecular Trost Annulation 
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 Meyer and co-workers used Trost’s strategy to form the C7-C22 fragment of 
amphidinolide K.20  Under their cyclization conditions THF precursor 1.58 forms both the 
tin alkoxide and palladium complex which undergoes cyclization to afford THF fragment 
1.59 in 88% yield (Scheme 23).  
 
Scheme 21. Synthesis of a THF Fragment of Amphidinolide K 
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2. Cobalt Catalyzed Oxidative Cyclization 
The use of molecular oxygen as an oxidizing agent is the most cost effective and 
atom economical choice for oxidation reactions (akin to H2 in reductions).  Unfortunately, 
molecular oxygen reactivity is typically not high enough to allow for it to be a useful 
reagent for most chemical transformations.  A number of methods have been developed to 
allow the use of oxygen as the stoichiometric oxidant in conjunction with a catalytic 
transition metal complex.1  Such oxidation reactions include, but are not limited to, 
epoxidation,2 olefin dehydrogenation,3 peroxygenation4 and alcohol oxidation.5   
2.1 The Mukaiyama Discovery  
In 1989 the Mukaiyama group was studying the use of molecular oxygen with 
cobalt catalysts to perform various oxidations of alcohols and alkenes.6  One such oxidation 
was the use of Co(L)2 type complexes (Figure 2) to produce trimethylsilylperoxides in 
good yield (Scheme 24).7 
                            
 
Scheme 22. Mukaiyama Trimethylsilylperoxide Synthesis 
 
Figure 2. Mukaiyama’s Ligands 
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Entry Alkene Time/h Product Yield 
1 
 
5 
 
95 
2 
 
12 
 
80 
3 
 
10 
 
99 
4 
 
12 
 
75 
a) Reaction conditions: Triethylsilane, alkene and Co(modp)2 reacted under O2 atmosphere in DCE.  
Table 1. Mukaiyama Silylperoxide Oxidation of Alkenes 
 This was accompanied by the use of an extended set of similar catalysts to perform 
oxidation, reduction, or hydrations of alkenes.8  Further extension of this work revealed 
that when subjecting a pent-4-ene-1-ol to the hydration reaction conditions, cyclization and 
oxidation occurred rather than olefin hydration (Scheme 24, Table 1)).  Various Co(II) 
complexes were examined from Co(tfa)2 (2.02) to Co(modp)2(2.01) (Figure 2).6  It was 
shown that the oxidative activity was present only in cobalt species with a reduction 
potential from approximately 0 and 0.5 eV relative to Ag/Ag+ in acetonitrile.9  This reactive 
range was demonstrated in Mukaiyama’s hydration chemistry and the trend holds true for 
the oxidative cyclization.  Electron withdrawing groups, located on the cobalt ligand, such 
as amides, esters, and trifluoromethyl groups, have been shown to produce cobalt species 
with reduction potentials in the 0.4 to 0.5 eV.  This range of cobalt species has produced 
the highest yields and selectivity towards to the cyclized THF product. In Mukaiyama’s 
case, the Co(modp)2 (2.01) catalyst proved to be the most effective and continued as the 
catalyst of choice.  The reaction conditions were optimized and it was found that moderate 
temperatures such as 50 °C were optimal as opposed to 75 °C, which resulted in lower 
yields and an increase in undesired side products with Co(tfa)2 (Table 2).  The addition of 
peroxides decreased reaction times and increased yields (Entries 5-7, Table 2).   
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Scheme 23. Mukaiyama’s Initial Discovery 
Entry Catalyst Temperature (°C) 
Additive  
(mol %) Time (h) 
Yield (%) 
2.07 2.08 
1 Co(tfa)2 75 - 4 21 24 
2 Co(tfa)2 50 - 8 55 0 
3 Co(acac)2 50 - 1 29 0 
4 Co(modp)2 50 - 0.5 62 0 
5 Co(modp)2 50 tBuOOH (50) 0.5 64 0 
6 Co(modp)2 50 tBuOOH (100) 0.5 73 0 
7 Co(modp)2 50 CHP (100) 0.5 71 0 
 
Table 2. Mukaiyama’s Initial Cyclization Optimization 
 
While providing good yields and excellent dr, the examples do not include any 
oxidatively sensitive functional groups or acid sensitive functional groups. Other major 
limitations of this study are substitution being limited to differentiation of the C2 position 
on the tetrahydrofuran ring and only terminal alkenes were explored (Table 3).  It was 
shown that electron donating and withdrawing groups had little effect on the reaction 
(Table 3, Entries 2 and 3), as did steric bulk (Table 3, Entry 8).  A decrease in yield was 
observed in substrates with bulky groups at the two position with dr remaining greater than 
97:3 trans:cis selectivity at the C2 and C5 positions.  
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Scheme 24. Mukaiyama Oxidative Cyclization 
 
Entry Substrate Product Yield (%) 
dr 
(trans %) 
1 
 
 
73 99 
2 
 
 
69 99 
3 
 
 
60 99 
4 
 
 
79 99 
5 
 
 
62 99 
6 
 
 
69 97 
7 
 
 
53 99 
8 
 
 
55 >99 
Table 3. Mukaiyama’s Substrate Scope for the Oxidative Cyclization 
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A mechanism was hypothesized by Mukaiyama in his original work, however, 
experimental validation of the proposed mechanism was absent.6  Mukaiyama 
hypothesized coordination of the cobalt catalyst to the alcohol and alkene sections of the 
pentenol (Scheme 27).  An oxygen-centered radical (I) is formed and stereoselectivity 
guided towards the alkene via π-bond interaction with the cobalt centre.  Due to steric 
factors, the cobalt complex resides opposite the R group (II) of the alkenol and forms a 
trans-THF junction.  This leaves a cobalt-stabilized radical (IV), which can either be 
oxidized by molecular oxygen then terminated with solvent to form the major hydroxylated 
THF product (2.08) or quenched before oxidation to form the alkyl THF (2.07).  
 
Scheme 25. Mukaiyamas Proposed Mechanism 
 
 
25 
 
 
 
2.2 Hartung’s Mechanism of the Mukaiyama Cyclization 
In a more recent work, the Hartung group has proposed an alternative mechanism,10 
in which the coordination of dioxygen to the paramagnetic cobalt  species forms a strong 
Lewis acid and metal oxidizing agent (Scheme 28).  The O2 cobalt species then coordinates 
to the alcohol in the starting material (Scheme 29).  Hartung states that Co(acac)2 
complexes have the ability to oxidize alkenes to the radical cation.  A single electron 
transfer occurs between the alkene and the Co(III) centre (VII).  Without the restraint of 
the double bond, the former alkene carbons are free to rotate into a more suitable chair 
transition state that allows for hydroxyl attack onto the cation to form the trans-THF ring 
(IX).  The reaction is terminated with quenching of the oxygen-centred radical to form the 
alcohol and loss of Co(III)OH (X).   
 
Scheme 26. Cobalt Activation of O2 
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Scheme 27. Hartung’s Proposed Mechanism 
IV 
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Hartung was able to provide evidence for his mechanism through an extensive 
substrate scope using a cobalt complex of 2.09 (Figure 3).  The proposed radical cation 
intermediate (VIII) was supported by the lack of diastereoselectivity when a non-terminal 
alkene was cyclized.  A similar observation was also seen by Pagenkopf and co-workers in 
2006 and is discussed in section 2.4.3 (Table 4).  These observations preclude an epoxide 
intermediate as high selectivity would be expected for such an intermediate.  A large 
substrate scope showed high diastereoselectivity towards 2,5-trans-configurations in the 
final product with 2,3 trans and 2,4 cis also giving moderate diastereoselectivity.  The latter 
relationships can be overcome by a stronger influence by 2,5 trans diastereoselectivity.  
This is attributed to the chair transition state involving the radical cation intermediate.   
 
Figure 4. Diastereoselectivity of the Mukaiyama Cyclization 
An important step in any catalytic sequence is regeneration of the catalyst.  As it is 
apparent that Co(III)OH will not catalyze the cyclization, there must be a pathway for the 
Figure 3.  Ligand Used in the Hartung Studies 
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renewal of the original complex.  The use of a suitable hydrogen donor proves vital to this 
sequence as the Co(III)OH (I, Scheme 30) by-product coordinates itself to a donor 
molecule (often iPrOH) and performs an oxidation to create the oxidized donor molecule 
and H2O, which are lost leaving the hydridocobalt(III) complex (III).  This is then reduced 
by abstraction by O2 (IV).  The production of acetone during mechanistic studies supported 
Hartung’s pathway.  During NMR studies using deuterated isopropanol- d8, it was found 
that solvent was a major proton source for termination of the radical species. 
 
 
Scheme 28. Catalyst Regeneration 
    
 
Hartung noted several limitations including the inability to form 2,5-substituted 
THFs with bulky substitution patterns in appreciable yield and pyran ring formation being 
inaccessible using the same reaction conditions.  Despite these limitations, increased utility 
for this chemistry was obtained by expanding the electrophiles that are capable of 
terminating the primary radical produced during the catalytic cycle.  By utilizing alternative 
reaction conditions, a toluene/cyclohexadiene (CHD) solvent system with added BrCCl3 
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can produce the primary bromide product (2.12, Scheme 31).11  Alternatively, CHD as the 
sole reaction solvent allows for reductive termination of the catalytic cycle to produce the 
fully reduced product (2.07). 
 
  
2.3 Applications 
Given the Mukaiyama oxidative cyclization’s inherent synthetic utility, several 
syntheses have been reported with the Co(II) catalyst as the THF-forming step.  The first 
was the synthesis of gigantetrocin A by Wang and Shi followed by Evans’ synthesis of 
mucocin (2.13).12  The Mukaiyama oxidative cyclization was also utilized by the 
Pagenkopf group in the synthesis of aplysiallene (2.24)13 and bullatacin (2.17)14, which 
will be addressed later in section 2.4.0. 
O
HO
O
OH
OHOH
O
O
9
2.13  
Figure 5. Mucocin 
 
 The synthesis of mucocin (2.13) shows how a rather simple starting material can 
very quickly be formed into a more complex molecule via oxidative cyclization of the 
appropriate precursor (Scheme 32).    Sharpless epoxide 2.14 is treated with allyl Grignard 
reagent to afford THF precursor 2.15.  Application of the cobalt-catalyzed oxidative 
 
Scheme 29.  Hartung Reductive Termination of an Oxidative Cyclization 
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cyclization conditions forms trans-THF ring 2.16, generating a new stereocentre with a 
very high degree of diastereocontrol.  This sequence demonstrates the convenience of the 
oxidative cyclization.   
 
Scheme 30. Oxidative Cyclization of Mucocin Precursor 
 
2.4 The Pagenkopf Group 
2.4.0 Natural Product Synthesis – Bullatacin and Aplysiallene 
A driving force for exploration of the Mukaiyama oxidative cyclization has been 
the pursuit of several natural product syntheses within the Pagenkopf group. Bullatacin14 
and aplysiallene13  have unique structural complexities and the former displaying high 
bioactivity making it an interesting target and a more complex application of the THF 
cyclization. 
 
Figure 6. Bullatacin 
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Scheme 31. Unprotected Cyclization Attempt 
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Scheme 32. Key Steps in the Synthesis of Bullatacin 
The synthesis of bullatacin (2.17), completed in 2006,15 utilized the Mukaiyama 
oxidation to create the central bis-THF core (2.22).14  The starting diepoxide was opened 
by allyl magnesium bromide to form dipentenol substrate 2.19. From the dipentenol 
substrate, a cyclization reaction would have produced the core of bullatacin, but despite a 
published precedent, the reaction proceeded in an unacceptable yield (Scheme 33).12  
Monoprotection of diol and performing the THF cyclization in a stepwise fashion produced 
the finished core in 45% over 7 steps (Scheme 34).   
Aplysiallene (2.24) contains an interesting fused bis-THF core, which under closer 
examination can be constructed in a similar manner to bullatacin (2.17).13  Unlike the 
synthesis of bullatacin, the THF core was successfully cyclized in good yield; however, 
attempts to desymmetrize the tetrahydrofuran core were unsuccessful.  Wang and 
Pagenkopf were then able to apply a similar strategy to that of the bullatacin synthesis to 
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access the THF core.  Initial desymmetrization of diol precursor 2.25 followed by two 
sequential cyclizations gave the THF core (2.27) of aplysiallene in good overall yield 
(Scheme 35).   
 
Figure 7. Aplysiallene 
 
 
 
Scheme 33. Key Steps in the Synthesis of Aplysiallene 
 
2.4.1 “Revamped” Synthesis of The Mukaiyama Ligands 
While being an efficient method of obtaining THF rings, the Mukaiyama catalyst 
was not without drawbacks. The catalyst is prepared using CoCl2 and KOH conditions in 
order to coordinate the morpholine derived ligand (modp) (Scheme 36). The catalyst also 
produced inconsistent yields in the cyclization of THF rings, and this is hypothesized to be 
due to low purity and decomposition of the catalyst.  The Pagenkopf group was able to 
redesign the synthetic route to the catalyst by utilizing cobalt-2-(ethylhexanoate)2 in place 
of CoCl2, which allowed for the complexation to occur in consistently good yield (Scheme 
37).16  Also, unlike the original procedure to produce the Mukaiyama catalyst, which was 
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a brown wax, the new method produced a crystalline powder allowing for convenient use 
in the laboratory setting. 
 
Scheme 34. Modp Ligand Synthesis 
 
 
 
 
 
 
2.4.2 Crystal Structures 
Throughout the course of the previously described natural product synthesis 
projects, effort was directed to the refinement and expansion of the Mukaiyama 
methodology.  Several variations of the cobalt catalysts were prepared in hopes of 
producing a catalyst with higher stability and overall performance in the oxidative 
cyclization.  Conveniently, x-ray quality crystals were obtained during these studies and 
N
O
O
OHO Co(2-ethylhexanoate)2 Co(modp)2
tan, crystalline powder
2
41%
2.01
Scheme 35. Synthesis of Co(modp)2 
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the structure of the catalyst was found.  At that point in time, very little structural 
information was known as the paramagnetic cobalt centre makes NMR experimentation 
near impossible.  After the synthesis of a broad range of ligands with varying substitution 
patterns, one was successfully crystallized in both the Co(II) and Co(III) oxidation states.16  
The Co(II) species was shown to be a bidentate structure with a single cobalt centre (Figure 
8).  The Co(III) species, however, was shown to contain two cobalt centres with bridging 
hydroxyl groups and two associated ligands (Figure 8). 
 
Figure 8. X-Ray Crystal structures of Co(DiBn)2 
 
2.4.3 Substrate Scope Exploration 
 Through a series of experiments conducted in the Pagenkopf lab15 the general 
reactivity scope of the cobalt catalyzed cyclization was explored (Table 4).  The reactivity 
     [Co
III
L2(µ-OH)]2 
 
 
 
[(CoIIL3)2CoII(OH2)6] 
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of the cobalt centre with various homoallylic alcohols was tested and it was found that they 
do not cyclize.  It is also important to note that the E/Z configuration of the alkene substrate 
is not affected by the reaction conditions and this selectivity allows for an enhanced 
synthetic utility (Scheme 38).  When both alkenes 2.32 and 2.33 were subjected to 
cyclization conditions, only the starting material was recovered.  The chemoselectivity and 
lack of isomerization allows a greater tolerance for external functionality on a substrate 
molecule, increases this methodology’s utility in synthesis.     
 
  
Scheme 36. Isomerization Experiment 
 
 Cyclization precursors with an exo-methylene unit gave the desired methyl-
substituted product in similar yield to the unsubstituted starting material (Entry 2, Table 4).  
Placing a geminal dimethyl group on the terminal end of the alkene resulted in the complete 
shutdown of reactivity, with only starting material obtained (Entry 3, Table 4).  Substitution 
on the two position of the alcohol gave a good yield, but only a 1.7:1 cis/trans 
diastereoselectivity (Entry 4, Table 4).  A pentanol with phenyl substitution at the three 
position was able to cyclize in good yield and produced an 8:1 (trans:cis) ratio at the 2,3 
substitution.  Similar results were also obtained by Hartung10, which assisted in elucidating 
the previously discussed mechanism (Scheme 29). An internal alkene could be cyclized 
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but without any selectivity towards the stereochemistry of the produced secondary alcohol.  
The internal alkene cyclization was performed using both cis and trans alkenes resulting 
in virtually the same product ratios, likely due to a common radical intermediate (Table 4, 
Entries 6-7).  
 
Scheme 37. Mukaiyama Oxidative Cyclization 
 
  
Entry Alcohol Product Yield 
1 
 
O
OH
HH
Ph
 
82 
2 Ph
OH
 
O
OH
H
Ph
 
75 
3 
Ph
OH
 
O
OH
H
Ph
 
0 
4 
HO
Ph  
O
OH
H
Ph  
83 
(1.7:1 cis/trans) 
5 
HO
Ph
 
O
OH
H
Ph  
75 
8:1 trans:cis) 
6 
Ph
OH
 
OPh
OH
H H
 
71% 
(1.2:1 syn:anti) 
7 
Ph
OH
 
OPh
OH
H H
 
53% 
(1.3:1 syn:anti) 
    
Table 4. Substitution Effect on dr. 
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2.5 Objectives of the Current Research 
 
Despite the high dr, simplicity of starting materials, and good yields of the 
Mukaiyama oxidative cyclization, there is great difficulty when attempting to remove the 
decomposed cobalt by-products while isolating the product.  During the purification of 
cyclization products with flash column chromatography, the green cobalt residue will 
streak on silica and coelute with the desired THF product.  Difficulty in obtaining purified 
products was amplified when attempting to scale-up reactions to produce large quantities 
of starting material for synthesis.  Even after multiple purification attempts, cobalt species 
may still remain and contaminate the product.  This is not only a problem because the 
product is impure but also because the paramagnetic cobalt species causes characterization 
via NMR spectroscopy to be difficult or in some cases 
impossible.  As this transformation played an integral part of 
many current synthetic projects within the Pagenkopf group, 
it was decided that dedication of resources to surmount this 
challenge was warranted.  The first and seemingly simplest option was to modify the 
existing ligands.  Many methods have been developed in order to overcome solubility 
problems in other catalytic reactions, these include but are not limited to sulfonated ligands 
and ionic liquids (Figure 9).17 These modifications aim to add functionality without 
affecting the desirable reactivity of the original ligand.  The method envisioned to work 
the best with the Mukaiyama catalyst was to modify the morpholine ring of the modp (2.01) 
ligand by replacing morpholine with a 1-methyl piperazine unit (2.37).  This would allow 
the ligand to be converted to the ammonium species and extracted via an acid workup.  
 
 Figure 9. Sulphonated Phosphine 
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Figure 10. Several CoL2 Ligands 
2.6 Results & Discussion 
With a (Z)-2-hydroxy-5,5-dimethyl-1-(4-methyl-1-piperazinyl)-2-hexene-1,4-
dione ligand (nmp) target in mind, the synthesis of a highly polar or ideally aqueous-soluble 
Mukaiyama catalyst began.18  The synthesis began with condensation of 1-
methylpiperazine with ethyloxalyl chloride (Scheme 40).  A subsequent Claisen 
condensation with pinacolone afforded the ligand.  Previously reported conditions called 
for the use of aqueous acetic acid to quench the reaction and form the enol product.  When 
these conditions were used in the synthesis of 2.37, poor yields were observed due to 
formation of the ammonium species and loss in the aqueous workup.  This was solved by 
using two equivalents of acetic acid in CH2Cl2 and a simple filtration to remove the residual 
potassium acetate salt.  Complexation of the ligand to the cobalt(II) centre was challenging 
as standard condition led to poor yields and a purple solid that performed poorly in the 
oxidative cyclization.  A purple color is indicative of unreacted cobalt(II) ethylhexanoate 
species, which interferes with the desired cyclization reaction. Previous studies within the 
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Scheme 38.  Synthesis of Co(nmp)2 
Pagenkopf group have provided crystallographic evidence that showed adventitious water 
in the crystal structure and its importance in synthesizing the various cobalt catalysts.16 
O O
O
N
N
2
Co(II)
2.38
 
Figure 11.  Cobalt NMP Catalyst 
It was found that the addition of several equivalents of water into the complexation 
mixture afforded a tan powder, which is a typical appearance for previous catalysts.  
 
  
 
This powder was subsequently tested against the standard piper (2.36) and modp (2.01) 
catalyst systems (Figure 10) with several TBS protected pentenols of varying side chain 
length (Table 5).  These were chosen due to their ease of separation from the standard 
cobalt complexes allowing a more accurate and reproducible yield of the desired catalyst.  
Comparing all three test substrates, the nmp catalyst (2.38) provided an efficient method 
of extraction and improved yields by up to 28%.  It is important to note that three methods 
EtO
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N
H
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2.38
2.37
2.402.28 2.39
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of extraction were examined: an aqueous acid wash (1 M HCl), a phosphate buffer wash, 
and methylation.  All three successfully removed the cobalt species from the reaction but 
the strong acid was abandoned in favour of the two milder options as strongly acidic 
conditions can cause decomposition of sensitive functionalities.   
 
Scheme 39.  Initial Co(nmp)2 Reaction Conditions 
 Yield % 
Entry Starting Material n 
modp 
(2.01) 
piper  
(2.36) 
nmp  
(2.37) a 
nmp 
(2.37) b 
1 2.41a 1 65 39 92 93 
2 2.41b 2 68 75 90 90 
3 2.41c 3 79 74 92 95 
a
 pH 4 phosphate buffer, b Methylation of the catalyst with MeI 
Table 5. Preliminary catalyst comparison 
 
After determining that the newly designed nmp catalyst (2.37) gave superior yields, 
experimentation into the optimal catalytic loading began (Table 6).  The modp catalyst 
performed optimally at catalyst loadings as low as 10 mol %.  Poor yields and by-product 
formation started to occur at low loadings using modp (2.01) and piper (2.36) ligands, along 
with complete consumption of the starting material.  As the cobalt species produced 
product it began to degrade and the degradation products began to decompose the THF 
methanol products.  In addition to decomposition pathways, the formation of reduction 
products could be observed as previously demonstrated by Mukaiyama.  In contrast, the 
nmp catalyst (2.38) proved to be effective with catalyst loadings as low as 5 mol % and 
degraded harmlessly at loadings of 3 and 1 mol %.  The lack of decomposition products 
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from the Co(nmp)2 allowed for the clean production of THF products and the absence of 
any observable THF methyl reduction products.  The production of a single product in 
exceptional yield contributed significantly to the ease of purification and subsequently to 
the synthetic utility of the newly designed catalyst (2.38). 
 
 
Scheme 40.  Co(L)2 Catalyst and Catalytic Loading Conditions 
Entry Catalyst Mol % Yield (%) 
1 Co(modp)2 15 68 
2 Co(modp)2 10 65 
3 Co(modp)2 5 47a 
4 Co(nmp)2 15 95 
5 Co(nmp)2 10 97 
6 Co(nmp)2 5 93 
7 Co(nmp)2 3 57 (93) b 
8 Co(nmp)2 1 10 (77) b 
a
 All starting material was consumed.  
b Yield based on recovered starting material.  
c Several examples were completed by Nick Morra and Barb Bajtos 
Table 6. Catalyst Loading Studies 
Initial Co(nmp)2 (2.38) results (Table 5 and 6) led to the examination of the 
versatility of the Co(nmp)2 catalyst and to determine if it was superior to the previous 
catalyst (Co(modp)2 (2.38) and Co(piper)2 (2.36)) across a wide variety of substrates.  The 
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substrates were put through reaction conditions with all three catalysts and various 
purification methods were employed with the Co(nmp)2 complex (2.38) (Table 7).  The 
use of a buffer wash was effective but did not offer any improvement in yield as compared 
to the piper catalyst (2.36) (Table 7).  These problems were also encountered initially with 
the methylation procedure but switching the extraction solvent from hexanes to 
dichloromethane allowed for an optimal extraction.  In all cases, the purified product was 
obtained in over 80% yield with many instances over 90% (Table 7). In some cases, a thin 
pad of silica was used to filter the catalyst from the reaction mixture.  While this method 
can be substrate-dependent it is by far the most efficient in those cases.  Two 
enantiomerically pure examples were prepared using the Co(nmp)2 catalyst.  These 
examples represent the core structures of Aplysiallene and Bullatacin.  The yields were 
either equal or superior to those reported in literature (Table 7, Entry 10-11).13,14 
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Scheme 41.  Substrate Scope Reaction Conditions 
 Yield % 
aEntry Product modp piper nmp MeI 
nmp 
buffer 
1 
 
69b 64b 85 54 
2 
 
20 58 90 66 
3 
 
29 81b 90 85 
4 
 
46 57 95 40 
5 
 
62 76 91 58 
6 
 
54 47 91 45 
8 
 
71 49 86 80 
9 
 
38 42 88 46 
10b 
 
55c 81 83 78 
11b 
 
69d 79 88 79 
 
a) Typical reaction conditions: cyclization precursor (1 eq), Co(nmp)2 (10 mol %), tBuOOH (10 mol %), iPrOH (10 mL), 
O2 (1 atm), 55 °C. b) This yield is a mixture of THF product contaminated with cobalt species that could not be removed 
by repeated chromatography. Thus, the yield is artificially elevated. c) See ref.13 d) See ref14. e)  Several examples were 
performed by Barb Bajtos, Andrew Stevens and Ben Machin. 
Table 7. Substrate Scope 
43 
 
 
 
2.7 Applications of Co(nmp)2 in Total Synthesis 
 
 Throughout the development of the Co(nmp)2 catalyst a major driving force for 
the research was the concurrent studies towards the total synthesis of amphidinolide C 
(2.43).  While the synthesis of this molecule was possible with Co(modp)2, the newly 
developed nmp ligand allowed for a higher yielding step as well a simplified and more 
practical application in the laboratory.  
 
Figure 12. Amphidinolide C and F 
 
 The C(18) to C(34) fragment of amphidinolide C was prepared by Nick Morra via 
the Mukaiyama cyclization (Scheme 44).19  Sharpless epoxide derived pentenol 2.45 was 
cyclized to the corresponding THF methanol product in 97 % yield.  The pendant alcohol 
serves as a functional handle for the construction of “tail” segment of the natural product 
(2.43).  Fragment 2.47 was efficiently synthesized on gram scale in high yield.  
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Scheme 42. The Gram Scale Synthesis of the C(18)-C(34) Fragment of Amphidinolide C 
 The C(1) – C(9) fragment of amphidinolide C was also constructed using the 
Mukaiyama cyclization to form the THF core (Scheme 45).20  The cyclization precursor 
was derived from a Sharpless epoxide but, unlike the previously described fragment, it 
required a one carbon homologation to give the required PMB ether.  Cyclization 
unsurprisingly gave the desired THF product in 92% yield.  Further functionalization was 
undertaken to prepare for an envisioned Stille coupling and macrolactonization.  Despite 
the efficient synthesis of all sections of amphidinolde C, the total synthesis of the target 
was not realized using this route.  
  
Scheme 43. The Gram Scale Synthesis of C(1) – C(9) Fragment of Amphidinolide C 
 
45 
 
 
 
In 2013, Furstner and co-workers completed the total synthesis of amphidinolide F 
using Co(nmp)2 catalyzed Mukaiyama oxidative cyclization (Scheme 46).21  An alkyne-
substituted precursor 2.51 was cyclized to afford THF methanol 2.52.  Alkyne-substituted 
THF 2.52 would allow for Furstner’s ring closing alkyne metathesis and esterification 
assembly steps.  Furstner also completed the total synthesis of amphidinolide C in 2015, 
utilizing a similar strategy to form the core of the molecule.22      
 
 
 
Scheme 44. Furstner’s Synthesis of the C(18)-C(28) fragment of Amphidinolide F 
   
2.8 Summary and Conclusions 
 
It has been over 25 years since the initial discovery of the Mukaiyama oxidative 
cyclization and in that time period it has been advanced to become an integral methodology 
in THF synthesis.  Many had observed the possible applications of Mukaiyama’s 
methodology and demonstrated its synthetic utility in total synthesis.  Even with a great 
deal of attention, it took several years before a mechanism was proposed and 
experimentally elucidated.  The Hartung group produced an important body of work in this 
field, allowing a great deal of development in the Mukaiyama methodology.  While in 
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search of a convenient purification method for products of the oxidative cyclization, a new 
nmp ligand suitable for the Mukaiyama oxidative cyclization was designed and 
synthesized.  The challenge of producing a catalyst with a simplified purification method 
was also met as it is now possible to remove the cobalt catalyst through acid extraction, 
methylation and ultimately a simple filtration.  The greatest achievement of this process 
was that the newly designed Co (nmp)2 catalyst was shown to produce a higher reactivity 
towards the pentanol substrates and more resistance to decomposition.  The novel 
Co(nmp)2 catalyst was subsequently applied in the synthesis of amphidinolide C and F, 
with replication of the previously observed high yields.  This newly developed catalyst is 
a great advancement in the Mukaiyama oxidative cyclization, and higher yields 
accompanied by improved purification techniques will allow for a broad range of use.  
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3. Application of Co(NMP)2 in Expanded THF Substitution Patterns   
 
3.1 Initial Scope Expansion for Co(nmp)2 
Results from the initial Co(nmp)2 (2.38) catalyst studies led to interesting questions 
about the reactivity of the catalyst.  One of these was that an exo dig type cyclization could 
be possible, thus leading to the formation of an enol. This enol could subsequently 
tautomerize to generate an aldehyde. Unfortunately, after 6 days under standard cyclization 
conditions both the TMS-protected (3.02) and unprotected (3.01) alkynols showed no 
cyclization product (Scheme 47).   
 
Scheme 45. Alkyne Oxidative Cyclization 
Another area of exploration that was envisioned was the ability to perform 
enantioselective transformations with the oxidative cyclization. This could potentially be 
introduced by modification of the ligand, where a chiral functionality is appended to one 
of the ligand ends (Figure 13).  The use of a chiral entity in place of the either the tBu group 
or the piperazine ring could possibly inovoke some enantioselectivity.   Ideally, this catalyst 
would react specifically with a single enantiomer of the parent pentenol and produce an 
enantio-enriched THF product.  Alternatively, this could facilitate the transformation of 
racemic pentenols to enantio-enriched substrate. To date, using camphor in place of 
pinacolone has been attempted but requires further investigation. 
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3.2 Synthesis of 2,2,6 – Trisubstituted THF Methanols  
 
There are many natural products in which oxygen heterocycles are substituted on 
the carbon atom adjacent the hetero atom (2,5 in the case of THFs).  Examples include 
monensin (Figure 14)1 and ionomycin (Figure 15).2  Monensin and ionomycin are in a class 
of compounds known as ionophores.  These molecules are able to coordinate to various 
ions from Ca(II) to Pb(II).  Monensin is used in the dairy and beef industries as it has been 
shown to improve the ability of cattle to metabolize feed.  This is due to the molecule’s 
ability to facilitate ion transportation through lipid membranes as an antiporter.3  In dairy 
cattle increased production of milk is observed along with lowered rates of gastrointestinal 
disease.3    
 
Figure 14. Monensin 
N
OH
O
NO
N
OH
O
NO
3.05 3.06
Figure 13.  Proposed Chiral nmp Ligands 
Scheme 46. Proposed Resolution using Co(nmp)2 
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 Ionomycin is a Ca(II) ionophore, which like Monensin, shows a high binding 
affinity to metal ion centres.  Ionophores have the ability to readily bind with calcium and 
facilitate it’s transport across lipid membranes, which has led to their application in 
biological studies of intracellular ion concentrations.   
 
Figure 15. Ionomycin 
Due to the interesting biological activities of Ionomycin, and other polyether ionophores, 
it has been the subject of synthetic studies.  Launtens and co-workers completed the 
synthesis of Ionomycin in 2002.2  The synthetic strategy towards the methyl-substituted 
THF core was a simple epoxidation/ cyclization.4  The geraniol-derived starting material 
was obtained in 7 steps from the naturally occurring terpenoid.  Using a vanadium catalyst 
and TBHP the trisubstituted alkene was epoxidized (Scheme 49).  Subsequent treatment 
with TsOH allowed for the cyclization product to be formed in a 7.8:1 mixture of the 
desired cis product over the trans.  Similar chemistry was subsequently used to create the 
second THF in the final natural product. 
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Scheme 47. Lautens THF Synthesis of Ionomycin 
 
3.3 Initial Studies with Co(nmp)2 
 With various natural products containing additional methyl functionality it was 
decided that functionality studies with the new Co(nmp)2 catalyst would begin.  Various 
substitution patterns have been tolerated by the oxidative cyclization on every position of 
the THF ring except trisubstitution in a 2,2,5 pattern.  Hartung showed that, using 
traditional ligands, the cyclization was unable to occur or occurred in very poor yields.10  
Preliminary experiments within the Pagenkopf lab found that Co(modp)2 was also unable 
to produce the cyclized methyl-substituted THF product in substantial yield but also 
performs a competitive hydration of the alkene (Scheme 50).  When Co(nmp)2 was used, 
the result was an almost 100% mass recovery and a mixture of cyclized product and starting 
material. 
 
 
Scheme 48. Methyl Substituted trans-THF Ring Formation 
 
53 
 
 
 
Initial studies carried out by Andrew Stevens5 gave trace amounts of the trans-THF 
product under the original NMP cyclization conditions but a simple increase in temperature 
from 50 °C to 80 °C afforded 72% yield of a mixture of starting material and desired 
product (Table 8).  This gave an excellent starting point for further optimization.  Increased 
catalyst loading was found to lower yields but increased the ratio of the desired product to 
starting material (Entries 2-4).  A significant increase in yield was observed with an 
increase in reaction concentration (Entries 5-10).   Solvent effects on the reaction were also 
manipulated in hopes of achieving higher yield.   It was hypothesized that solvents capable 
of increased O2 content would be beneficial to the transformation.  Trifluoroethanol, 
benzene, and dichloroethane all produced poor results in yield and product ratio whereas 
sBuOH showed quantitative mass recovery of starting material and product was observed, 
with a 7:1 product to starting material ratio (Entries 11-14).  The optimal catalyst loading 
was re-evaluated using sBuOH as the reaction solvent.  An optimal catalyst loading of 30 
% was found to give a quantitative yield of 9.7:1 product to starting material (Entries 15-
16).  The catalyst loading was found to be able to be reduced to 17.5 mol % without 
compromising the conversion, though lower loadings were unsuccessful (Entry 17).   
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Scheme 49. 2,2,5 Substituted THF Cyclization Conditions 
Entry Catalyst Loading (%) 
Conversion 
(sm/pdt) 
Yield 
(total)a Temp Solvent mL 
1 10 trace - 55 iPrOH 8 
2 10 2.5:1 72 80 iPrOH 8 
3 15 1.9:1 76 80 iPrOH 8 
4 20 1.3:1 69 80 iPrOH 8 
5 10 1.0:1.0 77 80 iPrOH 4 
6 20 1.0:5.2 81 80 iPrOH 4 
7 10 1.0/3.6 79 80 iPrOH 2 
8 20 1.0/5.2 80 80 iPrOH 2 
9 20 1.0/2.6 75 80 iPrOH 1 
10 20 1.0/1.8 77 80 iPrOH 0.5 
11 20 - - 70 CF3CH2OH 2 
12 20 1.0:7.2 quant 80 sBuOH 2 
13 20 1.0:2.6 - 70 C6H6 2 
14 20 1.0:1.4 - 70 C2H4Cl2 2 
15 30 1.0:9.7 quant 80 sBuOH 2 
16 15 1.0:4.7 quant 80 sBuOH 2 
17 17.5 1.0:5.1 quant 80 sBuOH 2 
a Yield is a weighted average of starting material to product as the overall conversion produced little to no by-products.  
b This work was completed by Andrew Stevens. SM = Starting Material, PDT = Product. 
Table 8. Optimization study on methyl substituted THFs 
 
 Although these initial findings were very promising, a serious problem was 
discovered by use of column chromatography to separate the starting material from the 
products. The recovered yields were significantly less than expected.  A simple experiment 
was conducted in which a known concentration of mesitylene, as an internal standard, was 
added to the crude product in order to determine if contamination by a salt or other NMR-
inactive compounds were the cause of the discrepancy between crude and purified yield.  
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The mesitylene peaks were integrated to known product peaks and the ratio was used to 
calculate the yield of product.  It was determined that indeed the crude yields were reliable 
and that the composition of the crude mixture was causing decomposition of the product 
upon flash-column chromatography.  Efforts were put towards an effective method for the 
purification of these THF products.  It appears that these trisubstituted THFs are unstable 
on silica gel and require other means of purification.  When an effective method of 
purification can be determined, a larger scope of substrates will be examined. 
Several different substrates were examined in order to see the effects of steric and 
electronics on the reaction.  Most reactions gave quantitative crude yields as a mixture of 
unconverted starting material and product (Table 9).  Both methyl and ethyl substitution 
were shown to be capable substrates in the reaction (Table 9, Entries 1-2).  Long-chain 
allyl and homo allyl substituents were also able to undergo the reaction although the allyl 
substrate performed poorly in the reaction.   The use of bulky sterically hindering groups 
gave poor yields (Entry 5), as did the electron donating phenyl acetylene group (Entry 6).  
Finally, oxaspirocycles were formed in modest yield in both the [4.5] and [4.4] varieties 
(Entries 7-8).   
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Figure 16. Conditions for methyl THF cyclization 
 
Entry Product Isolated Yield 
(%) brsm 
1 
 
42 (58) 
2 
 
56 (83) 
3 
 
55 (75) 
4 
 
20 (26) 
5 
 
25 (32) 
6 
 
19 (20) 
   
7 
 
41 (51) 
8 
 
39 (73) 
9 
 
0 
A
 Several examples were completed by Andrew Stevens. 
Table 9. Preliminary substrate scope for methyl substituted THFs 
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3.4  Applications of Co(nmp)2 in the Synthesis of Cyclocapitelline 
 
 The newly discovered capability of the Mukaiyama oxidative cyclization with 
Co(nmp)2 to produce 2,2,5 substituted THF rings was utilized in the synthesis of 
cyclocapitelline (Scheme 52).5  Geoff Phillips used a geraniol-derived tertiary alcohol 3.17 
was cyclized under the optimized reaction conditions developed in the previously described 
substrate exploration.  The cyclization of 3.17 produced a mixture of diastereomers of 3.18 
in a 3:1 (trans:cis) ratio.  This mixture was used without separation to access 
cyclocapitelline (3.19) and isocyclocapitelline in 12 steps from geraniol.   
 
Scheme 50.  The Synthesis of Cyclocapitelline 
3.5 Oxime Synthesis with Co(nmp)2 
 Yu and co-workers utilized the Co(nmp)2 catalyst in their synthesis of β,γ-
unsaturated oxazolines (Scheme 53).6  Yu determined the under standard Co(nmp)2 
cyclization conditions an oxime such as 3.21 can be cyclized to form 4,5 
dihydroisooxazoles in good yield.  Substitution on the α-carbon gave diastereoselectivity 
but with no example over 2:1. Alternatively, the Co(nmp)2 catalyst can be subjected to 
Hartung’s conditions using CHD in toluene to produce the reduced methyl product (3.20).7  
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The Co(nmp)2 catalyst gave good yields under these conditions, consistent with those under 
oxidative conditions. 
 
Scheme 51.  Yu Cyclization of Oximes  
 
3.6 Summary and Conclusion 
There has been significant progress towards expanding several new substitution 
patterns within the substrate scope.  Developing a better understanding of product 
decomposition will be essential to fully understand the limits of this reaction and efforts 
are already underway to fully explore this.  This will include the use of protecting groups 
or other derivatization to stabilize the molecule for purification and possibly the 
development of a different method of purification. The use of Co(nmp)2 to cyclize new 
varieties of compounds has greatly expanded the scope and future possibilities of these 
reactions in natural product synthesis.  I have successfully examined 2,2,5-trisubstituted 
THFs in varying degrees of complexity.  Subsequently, the synthesis of cyclocapitelline 
was accomplished using the Co(nmp)2 catalyst and the reaction conditions developed for 
trisubstituted.  An interesting application to the synthesis of oximes was also undertaken 
by the Yu group.  Overall, the Co(nmp)2 catalyst has allowed for the expansion of the 
Mukaiyama oxidative cyclization substrate scope and will be at the forefront of any further 
developments in this field. 
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4. Experimental Procedures 
 
All reactions were run under an argon atmosphere unless otherwise indicated. 
Flasks were oven-dried and cooled in a desiccator prior to use unless water was used in the 
reaction. Solvents and reagents were purified by standard methods.1 Dichloromethane, 
diethyl ether, and tetrahydrofuran (THF) were purified by passing the solvents through 
activated alumina columns.  iso-Propanol (99.5%, 0.2%  H2O) was used as received from 
Caledon Laboratory Chemicals.  All other chemicals were of reagent quality and used as 
obtained from commercial sources unless otherwise noted. The progress of reactions were 
monitored by thin layer chromatography (TLC) performed on F254 silica gel plates. The 
plates were visualized by staining with ceric ammonium molybdate (CAM)2 or p-
anisaldehyde. Column chromatography was performed with Silica Flash P60 60 Å silica 
gel from Silicycle according to the Still method.3 Centrifugations were conducted with an 
International Clinical Centrifuge model CL at approx. 8000 rpm for 10 min (International 
Equipment Company, USA). 
 
The 1H and 13C NMR data were obtained on 400 or 600 MHz spectrometers. All 
spectra were obtained in deuterated chloroform and were referenced to residual chloroform 
at δ 7.25 ppm for 1H spectra and the center peak of the triplet at δ 77.0 (t) for 13C spectra. 
When peak multiplicities are given, the following abbreviations are used: s, singlet; d, 
doublet; dd, doublet of doublets; ddd, doublet of doublet of doublets; t, triplet; q, quartet; 
m, multiplet; br, broad; app, apparent. EI high resolution mass spectra were obtained using 
a spectrometer at an ionizing voltage of 70 eV. Melting points are uncorrected. 
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Synthesis of Co (nmp)2 
 
Ethyl 2-(4-methylpiperazin-1-yl)-2-oxoacetate (2.40) 
 
To a solution of N-methylpiperazine (22.2 mL, 200 mmol, 1 eq) and triethyl amine (27.8 
mL, 200 mmol, 1 eq) in CH2Cl2 (200 mL) at 0 °C was added ethyl oxalyl chloride (22.4 
mL, 200 mmol, 1 eq).  The reaction was warmed to room temperature and stirred for 16 h.  
The resulting heterogeneous mixture was quenched with NaHCO3 solution (200 mL) and 
the phases were separated.  The aqueous phase was extracted with CH2Cl2 (3 × 100 mL), 
the organic phases were combined and washed with brine (200 mL), dried over anhydrous 
MgSO4 and concentrated under reduced pressure to afford an orange oil (39.6 g, 99%). The 
product was used without further purification. Rf 0.10 (66% EtOAc/Hex); 1H NMR (400 
MHz, CDCl3) δ 4.30 (q, J = 7.2 Hz, 2H), 3.64-3.61 (m, 2H), 3.43-3.41 (m, 2H), 2.42-2.40 
(m, 4H), 2.29 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 162.9, 160.3, 
62.3, 55.1, 54.3, 46.2, 41.4, 14.2; HRMS m/z calcd for C9H16N2O3 [M+H+]: 200.1161, 
found: 200.1163. 
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(Z)-2-Hydroxy-5,5-dimethyl-1-(4-methylpiperazin-1-yl)hex-2-ene-1,4-dione (2.37) 
 
A solution of tert-BuOK (4.48 g, 40 mmol, 2 eq) in THF (100 mL) was added to a solution 
of pinacolone (2.50 mL, 20 mmol, 1 eq) and glycoxylate 2.40 (4.00 g, 20 mmol, 1 eq) in 
THF (20 mL) at 0°C and warmed to rt (room temperature).  The mixture was stirred at 
room temperature for 16 h and subsequently treated with 40 mL of 1M HOAc in CH2Cl2.  
After stirring for 0.5 h the slurry was filtered through celite and concentrated under reduced 
pressure to afford an orange syrup (4.32 g, 85%). The product was used without further 
purification. Rf 0.15 (5% MeOH/EtOAc); 1H NMR (400 MHz, CDCl3) δ 5.97 (s, 1H), 3.66-
3.58 (m, 4H), 2.46-2.43 (m, 4H), 2.31 (s, 3H), 1.19 (s, 9H). 13C NMR (100 MHz, CDCl3) 
δ 200.9, 185.3, 163.8, 95.3, 55.1, 54.3, 45.8, 41.6, 27.2; HRMS m/z calcd for C13H22N2O3 
[M+H+]: 254.1630, found: 254.1644. 
CoII(nmp)2 (2.38) 
 
To a solution of NMP ligand 2.37 (2.54 g, 10 mmol, 2 eq) in benzene (50 mL) was added 
Co(II) ethylhexanoate (65 wt % solution, 1.88 M in mineral spirits, 5 mmol, 1 eq).  The 
reaction was stirred for 10 min, water (0.36 mL, 20 mmol) was added and the reaction 
stirred for 16 h at rt.  Hexanes (200 mL) was added and the brown solids were separated 
by centrifugation.  The solids were triturated with hexanes and this was repeated an 
additional three times. The product was then transferred to a flask and the remaining 
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solvent was removed under reduced pressure to afford the Co(NMP)2 catalyst (2.69 g, 95%) 
as a beige solid.  LRMS: m/z [M + Na]+ calc. for C78Co3H126 N12NaO18: 1718.72; found: 
1718.8; combustion analysis: calc. for Co(NMP)2·(H2O)3.5, C 49.68, H 7.86, N 8.91; found: 
C 49.58%, H 7.53%, N 8.84%. Based on previously obtained crystal structures of related 
compounds,4 it is believed that the structure of the catalyst is similar, comprised of three 
cobalt atoms and six ligands per unit cell.  Two outer cobalt atoms, each surrounded by 
three ligands, flank an inner cobalt atom.  Inclusion of water in the crystal structure is 
likely, as elemental analysis of samples after prolonged drying over P2O5 in a drying pistol 
results in data that requires 3.5 water molecules per cobalt atom. 
Synthesis of Pentenol substrates and products 
General Grignard Procedure:  
A 250 mL round bottom flask equipped with a reflux condenser was charged with allyl 
magnesium bromide (1.0 M solution in ether, 60 mL, 60 mmol, 1.3 eq) and cooled to 0 °C 
with a water-ice bath. The epoxide (46.1 mmol, 1 eq) was added through the reflux 
condenser manually via syringe at a rate that produced a steady reflux.  Once the addition 
was complete, the condenser was washed with 10 mL of dry diethyl ether and the ice bath 
was removed.  After 0.2 h excess allyl magnesium bromide was quenched with half 
saturated aqueous NH4Cl and the aqueous layer was extracted with diethyl ether (3 × 20 
mL).  The combined organic layers were washed with brine, dried (MgSO4), filtered 
through celite and concentrated under reduced pressure. 
 
General Grignard Addition to Aldehydes Procedure: A 250 mL round bottom flask 
equipped with a reflux condenser was charged with homoallyl magnesium bromide (1.0 M 
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solution in ether, 60 mL, 60 mmol, 1.3 eq) and cooled to 0 °C with a water-ice bath. The 
aldehyde (46.1 mmol, 1 eq) was added through the reflux condenser manually via syringe 
at a rate that produced a steady reflux.  Once the addition was complete the condenser was 
washed with 10 mL of dry diethyl ether and the ice bath was removed.  After 0.2 h excess 
allyl magnesium bromide was quenched with half saturated NH4Cl and the aqueous layer 
was extracted with diethyl ether (3 × 20 mL).  The combined organic layers were washed 
with brine, dried over MgSO4, filtered through celite and concentrated under reduced 
pressure. 
General Cyclization Procedure: The cyclization precursor (1.0 mmol, 1.0 eq) was added 
as a solution in 10 mL iPrOH to a flask charged with Co(L)2 (0.10 mmol, 0.10 eq) under 1 
atm of O2 (balloon). At room temperature, tert-butyl hydroperoxide (5.33 M in isooctane, 
19 μL, 0.1 mmol, 0.1 eq) was added in one portion, and the resulting solution was heated 
at 55 °C for 16 h.  The crude reaction mixture was purified using one of the methods listed 
below. 
Purification Procedure A (Co(modp)2 and Co(piper)2:  The reaction mixture was 
concentrated under reduced pressure and the residue was purified by flash chromatography 
on silica gel using EtOAc-hexanes for elution  
Purification Procedure B (Co(NMP)2 methylation):  The reaction mixture was cooled 
to rt, purged of O2 with argon and methyl iodide (62 μL, 1.0 mmol, 1.0 eq) was added.  
After 16 h the reaction mixture was concentrated under reduced pressure and the residue 
was dissolved in water (20 mL) and CH2Cl2 (20 mL). The layers were separated and the 
aqueous layer was extracted with CH2Cl2 (4 × 20 mL). The combined organic layers were 
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washed with brine, dried MgSO4, filtered through celite and concentrated under reduced 
pressure.  
Purification Procedure C (Co(NMP)2 buffer wash): The reaction mixture was 
concentrated under reduced pressure and the residue was dissolved in hexanes (20 mL) and 
buffer (20 mL, pH 5.5). 
 The heterogeneous mixture was separated and the aqueous layer was extracted with 
hexanes (4 × 20 mL). The combined organic layers were washed with buffer, brine, dried 
(MgSO4), filtered through celite and concentrated under reduced pressure.  
Purification Procedure D (Co(NMP)2 acid wash):  The reaction mixture was 
concentrated under reduced pressure and the residue was dissolved in hexanes (20 mL) and  
1 M HCl (20 mL). The heterogeneous mixture was separated and the aqueous layer was 
extracted with hexanes (4 × 20 mL). The combined organic layers were washed with buffer, 
brine, dried with anhydrous MgSO4, filtered through celite and concentrated under reduced 
pressure. 
Purification Procedure E (Silcia Gel Filtration):   The reaction mixture was filtered 
through a thin pad of silica layered on top of a thin pad of celite.  The reaction flask and 
silica pad were washed with an additional 100 mL of EtOAc.   The EtOAc filtrate solution 
was concentrated under reduced pressure. 
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(5-((tert-Butyldimethylsilyloxy)methyl)tetrahydrofuran-2-yl)methanol (2.42a) 
 
The title compound was prepared using the general cyclization procedure to afford a clear 
yellow oil (39 – 93%). Rf 0.33 (33 v/v % EtOAc/Hex); 1H NMR (400 MHz, CDCl3) δ 4.13-
4.04 (m, 2H), 3.66-3.57 (m, 3H), 3.47 (dd, J = 11.4, 6.2 Hz, 1H), 2.01-1.93 (m, 2H), 1.89 
(br s, 1H), 1.79-1.73 (m, 1H), 1.71-1.65 (m, 1H), 0.89 (s, 9H), 0.05 (s, 6H); 13C NMR (100 
MHz, CDCl3) δ 79.8, 79.7, 65.9, 64.9, 28.2, 27.3, 25.9, 18.4, −5.3; HRMS m/z calcd for 
C12H26O3Si [(M+H)+]: 247.1729, found: 247.1729.   
(S)-1-(tert-Butyl-dimethyl-silanyloxy)-hept-6-en-3-ol (2.41a) 
 
The title compound was prepared using the general Grignard procedure, to afford a clear 
colorless oil (99.6%, 11.24 g) which was used without further purification. Rf 0.60 (30 v/v 
% EtOAc/Hex); 1HNMR (400 MHz, CDCl3) δ  5.83 (ddd, J = 17.1, 10.3, 6.6 Hz, 1H), 5.08-
4.92 (m, 2H), 3.92-3.78 (m, 3H), 3.45 (br s, 1H), 2.25-2.05 (m, 2H), 1.72-1.48 (m, 4H), 
0.89 (s, 9H), 0.07 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 138.7, 114.5, 71.6, 62.8, 38.2, 
36.6, 29.8, 25.8, 18.1, -5.5. 
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1-(tert-Butyldimethylsilyloxy)oct-7-en-4-ol (2.41c) 
 
The title compound was prepared using the general Grignard procedure, to afford colorless 
oil (95%, 3.2 g).  Rf 0.58 (30 v/v % EtOAc/Hex); 1H NMR (400 MHz, CDCl3) δ 5.85-5.75 
(m, 1H), 5.01 (dd, J = 17.2, 1.2 Hz), 4.91 (dd, J = 10.2, 1.2 Hz), 3.64-3.49 (m, 3H), 2.74 
(br s, 1H), 2.20-2.06 (m, 2H), 1.65-1.33 (m, 6H), 0.86 (s, 9H), 0.03 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 138.7, 114.5, 70.8, 63.5, 36.4, 34.6, 30.1, 29.0, 25o.9, 18.2, -5.4; HRMS 
m/z calcd for C14H30O2Si [(M+H)+]: 259.2093, found: 259.2089. 
(5-(3(tert-Butyldimethylsilyloxy)-propyl)tetrahydrofuran-2-yl)methanol (2.42c) 
 
The title compound was prepared using the general cyclization procedure to afford a clear 
yellow oil (74 - 95%). Rf 0.30 (33 v/v % EtOAc/Hex); 1H NMR (400 MHz, CDCl3) δ 4.09 
(ddd,  J = 14.1, 6.6, 3.5 Hz, 1H), 3.97-3.92 (m, 1H), 3.64-3.59 (m, 3H), 3.49-3.45 (m, 1H), 
2.06-2.00 (m, 1H), 1.98-1.94 (m, 1H), 1.92-1.87 (m, 1H), 1.69-1.47 (m, 6H), 0.88 (s, 9H), 
0.03 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 79.3, 78.8, 65.1, 63.1, 32.1, 32.0, 29.5, 27.5, 
25.9, 18.3, −5.3; HRMS m/z calcd for C14H30O3Si [(M+H)+]: 275.2042, found: 275.2032. 
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1-(Methoxymethoxy)oct-7-en-4-ol (Table 7, Entry 1) 
 
The title compound was prepared using the general Grignard procedure, to afford a 
colorless oil (44%, 0.592 g). Rf 0.32 (33 v/v % EtOAc/Hex); 1H NMR (400MHz, CDCl3) 
δ 5.84 (ddt, J = 17.0, 10.3, 6.6 Hz, 1H), 5.05 (ddd, J = 17.2, 3.5, 1.6 Hz, 1H), 4.97 (ddd, J 
= 10.2, 3.3, 1.4 Hz, 1H), 4.63 (s, 2H), 3.65 (br s, 1H), 3.57 (t, J = 6.3 Hz, 2H), 3.36 (s, 3H), 
2.27-2.16 (m, 1H), 2.16-2.04 (m, 2H), 1.79-1.69 (m, 2H), 1.66-1.60 (m, 1H), 1.58-1.46 (m, 
3H); 13C NMR (100 MHz, CDCl3) δ 138.6, 114.7, 96.4, 71.0, 67.9, 55.2, 36.6, 34.5, 30.0, 
26.0; HRMS m/z calcd for C10H20O3 [(M+H)+]: 189.1491, found: 189.1506. 
(5-(3-(Methoxymethoxy)propyl)tetrahydrofuran-2-yl)methanol (Table 7, Entry 1) 
 
The title compound was prepared using the general cyclization procedure to afford a light 
yellow oil (54 – 85%). Rf 0.05 (30 v/v % EtOAc/Hex); 1H NMR (400 MHz, CDCl3)  δ6.83 
(s, 4H), 4.14-4.12 (m, 1H), 4.04-3.91 (m, 3H), 3.77 (s, 3H), 3.67-3.62 (m, 1H), 3.52-3.51 
(m, 1H), 2.10-1.95 (m, 3H), 1.89-1.77 (m, 3H), 1.74-1.55 (m, H); 13C NMR (100HMz, 
CDCl3) δ 153.7, 153.1, 115.4, 114.6, 79.0, 78.9, 68.4, 65.0, 55.7, 32.1, 32.0, 27.5, 6.1; 
HRMS m/z calcd for [(M+H)+]: 205.1440, found: 205.1427. 
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1-(Benzyloxy)oct-7-en-4-ol (Table 7, Entry 2) 
 
The title compound was prepared using the general Grignard procedure, to afford yellow 
oil (47%, 1.01 g) Rf 0.32 (33 v/v % EtOAc/Hex); 1H NMR (400MHz, CDCl3) δ  7.36-7.27 
(m, 5H), 5.83 (ddt, J = 17.1, 10.3, 6.6 Hz, 1H), 5.03 (ddd, J = 17.2, 3.5, 2.0 Hz, 1H), 4.95 
(ddd, J = 10.2, 3.1, 1.2 Hz, 1H), 4.51 (s, 2H), 3.65-3.59 (m, 1H), 3.55-3.46 (m, 3H), 2.25-
2.16 (m, 1H), 2.14- 2.09 (m, 1H), 1.79 – 1.70 (m, 2H), 1.56-1.45 (m, 3H); 13C NMR (100 
MHz, CDCl3)  δ 138.6, 128.4, 127.7, 114.6, 73.0, 70.48, 36.5, 34.7, 30.0, 26.1;  HRMS 
m/z calcd for [M+]: 234.1620, found: 234.1627. 
1-(4-Methoxyphenoxy)oct-7-en-4-ol (Table 7, Entry 3) 
 
The title compound was prepared using the general Grignard procedure, to afford dark 
orange oil (82%, 1.514 g).  Rf 0.32 (30 v/v % EtOAc/hex);  1H NMR (400 MHz, CDCl3)  
δ 6.80 (s, 4H), 5.82 (ddt,  J = 17.0, 10.1, 6.8 Hz, 1H), 5.03 (d, J = 16.0 Hz, 1H), 4.96 (d, J 
=  10.2 Hz, 1H), 3.91-3.86 (m, 2H), 3.72 (s, 3H),  3.65-3.64(m, 1H), 2.49 (br s, 1H), 2.24-
2.09 (m, 2H),  1.91-1.77 (m, 2H), 1.69-1.61 (m, 1H), 1.57-1.49 (m, 3H); 13C NMR (100 
MHz, CDCl3) δ 153.8, 152.83, 138.34, 116.0, 115.26, 114.43, 70.7, 68.46, 55.46, 36.35, 
33.85, 29.85, 25.48; HRMS m/z calcd for C15H22O3 [M+]: 250.1569, found: 250.1568. 
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(5-(3-(4-Methoxyphenoxy)propyl)tetrahydrofuran-2-yl)methanol (Table 7, Entry 3) 
 
The title compound was prepared using the general cyclization procedure to afford a clear 
yellow oil (39 – 93%). Rf 0.24 (50 v/v % EtOAc/Hex); 1H NMR (400 MHz, CDCl3) δ 6.83 
(s, 4H), 4.14-4.12 (m, 1H), 4.04-3.91 (m, 3H), 3.77 (s, 3H), 0.77 (m, 1H), 3.52-3.51 (m, 
1H), 2.08-1.98 (m, 3H), 1.89-1.77 (m, 3H), 1.74-1.55 (m, 4H); 13C NMR (100 MHz, 
CDCl3)  δ 153.7, 1.53.1, 115.4, 114.6, 78.9, 68.4, 65.0, 55.7, 32.1, 32.0, 27.5, 26.12; HRMS 
m/z calcd for C15H22O4 [M+]: 266.1518, found: 266.1509. 
Nona-1,8-dien-5-ol (Table 7, Entry 4) 
 
The title compound was prepared using the general Grignard procedure, to afford a clear 
colourless oil (81%, 1.59 g) Rf 0.35 (20 v/v % EtOAc/Hex); 1H NMR (400 MHz, CDCl3) 
δ 5.88-5.78 (m, 2H), 5.04 (d, J = 16.8 Hz, 2H), 4.96 (d, J = 10.2 Hz, 2H), 3.64 (br s, 1H), 
2.23-2.08 (m, 4H), 1.61-1.49 (m, 5H); 13C NMR (100 Hz, CDCl3)  δ 138.5, 114.7, 70.9, 
36.5, 30.0; HRMS m/z calcd for C9H16O [M+]: 140.1201, found: 140.1202.  
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(5-(But-3-enyl)tetrahydrofuran-2-yl)methanol (Table 7, Entry 4) 
 
The title compound was prepared using the general cyclization procedure to afford a clear 
yellow oil (40 – 95%). Rf 0.2 (30 v/v % EtOAc/Hex); 1H NMR (400 MHz, CDCl3) δ 5.84-
5.78 (m, 1H), 5.04-4.93 (m, 2H), 4.09 (ddd, J = 10.5, 6.4, 3.5 Hz, 1H), 3.96-3.91 (m, 1H), 
3.61 (dd, J = 10.4, 3.2 Hz, 1H), 3.47 (dd, J = 11.4, 6.2 Hz, 1H), .22- 2.00 (m, 4H), 1.98-
1.92 (m, 1H), 1.72-1.62 (m, 2H), 1.56-1.49 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 138.3, 
114.6, 78.8, 78.8, 64.9, 34.8, 31.9, 30.4, 27.5; HRMS m/z calcd for C9H16O2 [(M+H)+]: 
157.1229, found: 157.1232.  
 
1-phenylhept-6-en-3-ol (Table 7, Entry 7) 
 
The title compound was prepared according to the general Grignard addition to aldehydes 
procedure to afford a clear colourless oil (90%, 2.00 g).  Rf 0.48 (30 v/v % EtOAc/hexanes); 
1H NMR (600 MHz, CDCl3) δ 7.32-7.29 (m, 2H), 7.23-7.19 (m, 3H), 5.85 (ddt, J = 17.0, 
10.3, 6.6 Hz, 1H), 5.06 (dq, J = 17.0, 1.8 Hz, 1H), 4.99 (dd, J = 10.0, 1.2 Hz, 1H), 3.68-
3.64 (m, 1H), 2.81 (ddd, J = 14.1, 10.0, 5.9, 1H), 2.68 (ddd, J = 13.8, 9.7, 7.0 Hz, 1H), 
2.25-2.19 (m, 1H), 2.17-2.11 (m, 1H), 1.83-1.73 (m, 2H), 1.64-1.54 (m, 2H); 13C NMR 
(150 MHz, CDCl3)  δ 142.0, 138.4, 128.3, 125.7, 114.7, 70.77, 39.0, 36.5, 32.0, 30.0; 
HRMS m/z calcd for C13H18O [M+]: 176.1201, found: 176.1195.  
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(5-phenethyltetrahydrofuran-2-yl)methanol (Table 7, Entry 8) 
 
The title compound was prepared using the general cyclization procedure to afford a clear 
yellow oil (49 – 86%). Rf 0.23 (30 v/v % EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 
7.31-7.18 (m, 5H), 4.18-4.12 (m, 1H), 4.00- 3.93 (m, 1H), 3.65 (ddd, J = 11.3, 7.0, 3.1 Hz, 
1H), 3.50 (dt, J = 11.5, 6.0 Hz, 1H), 2.79-2.63 (m, 2H), 2.09-1.88 (m, 4H),1.82-1.55 (m, 
3H); 13C NMR (150 MHz, CDCl3) δ 141.9, 128.3, 128.2, 125.7, 78.9, 64.9, 37.3, 32.4, 
31.9, 27.5; HRMS m/z calcd for C13H18O2 [M+]: 206.1307, found: 206.1309; combustion 
analysis: calc. for C13H18O2, C 75.69, H 8.80; found: C 75.01%, H 8.62%.  
(E)-(5-styryltetrahydrofuran-2-yl)methanol (Table 7, Entry 9) 
O
OH
H H
 
The title compound was prepared using the general cyclization procedure to afford a clear 
yellow oil (38 - 88%). Rf 0.34 (40 v/v % EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 
7.40-7.20 (m, 5H), 6.58 (d, J = 16.0 Hz, 1H), 6.19 (dd, J = 16.0, 6.6 Hz, 1H), 4.59 (q, J = 
6.6 Hz, 1H), 4.26-4.20 (m, 1H), 3.70 (dd, J = 11.7, 3.1 Hz, 1H), 3.54 (dd, J = 11.7, 5.9 Hz, 
1H), 2.21-2.13 (m, 1H), 2.07-2.00 (m, 1H), 1.83-1.72 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 136.7, 130.8, 130.1, 128.5, 127.6, 126.5, 80.0, 79.6, 65.1, 33.1, 27.6; HRMS m/z 
calcd for C13H16O2 [M+]: 204.1150, found: 204.1158. 
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The following compounds have been previously reported: Compounds 6a,5 7b,6 Table 3, 
Entry 2, Product;7 Table 3, Entry 5, Starting Material;8  Table 3, Entry 5, Product;9  Table 
3, Entry 6, Starting Material;10  Table 3, Entry 6, Product;  Table 3, Entry  7, Starting 
Material;11  Table 3, Entry 7, Product;6  Table 3, Entry 10, Starting Material; Table 3, Entry 
9, Starting Material;12  Table 3, Entry 10, Product;  Table 3, Entry 11 Starting Material;  
Table 3, Entry 11, Product.  
Synthesis of Hexenol substrates 
General Procedure for Cyclization: The cyclization precursor (1.0 mmol, 1.0 eq) was 
added to a solution of 2 mL sBuOH and preoxidized Co(L)2 (0.10 mmol, 0.10 eq) under 1 
atm of O2 (balloon).  The resulting solution was heated at 70 °C for 16 h.  The crude 
reaction mixture was filtered through a thin pad of silica and washed with CH2Cl2.  The 
crude product was purified by silica chromatography (gradient 10 v/v % to 40 v/v %, 
EtOAc/Hexanes).  
 
 
General Procedure for Grignard Addition to Ketones:  
 
A 250 mL round bottom flask equipped with a reflux condenser was charged with alkyl 
magnesium bromide 1.0 M solution in ether, 60 mL, 60 mmol, 1.3 eq) and cooled to 0 °C 
with a water-ice bath. The ketone (46.1 mmol, 1 eq)  was added through the reflux 
condenser manually via syringe at a rate that produced a steady reflux.  Once the addition 
was complete the condenser was washed with 10 mL of dry diethyl ether and the ice bath 
was removed.  After 0.2 h excess alkyl magnesium bromide was quenched with half 
saturated NH4Cl and the aqueous layer was extracted  with diethyl ether (3 x 20 mL).  The 
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combined organic layers were washed with brine, dried over MgSO4, filtered through celite 
and concentrated under reduced pressure. 
 
2-Phenylhex-5-en-ol (3.13) 
 
The title compound was prepared using the general Grignard addition to ketones procedure 
to afford a light yellow oil (85%, 1.72 g). Rf  0.44 (20 v/v % EtOAc/hexanes); 1H NMR 
(400 MHz ,CDCl3) δ 7.57 (d, J = 7.0 Hz, 1 H), 7.37 - 7.44 (m, 3 H), 7.31 (t, J = 7.8 Hz, 2 
H), 7.18 - 7.25 (m, 2 H), 5.67 - 5.86 (m, 1 H), 4.85 - 4.98 (m, 2 H), 2.00 - 2.05 (m, 1 H), 
1.83 - 1.94 (m, 3 H), 1.75 (s, 1 H), 1.51 - 1.56 (m, 3 H); 13C NMR (100 MHz, CDCl3) δ 
147.7, 138.2, 128.6, 126.6, 124.7, 114.5, 74.7, 43.0, 30.4, 28.5; HRMS m/z calcd for 
C12H16O [M+] 176.1201, found: 176.1199. 
(2-Methyl-2-Phenyltetrahydrofuran-2-yl) methanol (3.14) 
 
The title compound was prepared using the general cyclization procedure to afford alight 
yellow oil (42%, 40.4 mg). Rf 0.23 (20 v/v % EtOAc/hexanes); 1H NMR (600 MHz 
,CDCl3) δ 7.38 - 7.45 (m, 2 H), 7.30 - 7.35 (m, 2 H), 7.20 - 7.24 (m, 1 H), 4.13 - 4.24 (m, 
1 H), 3.76 (d, J = 11.7 Hz, 1 H), 3.51 - 3.61 (m, 1 H), 2.21 - 2.30 (m, 1 H), 1.99 - 2.18 (m, 
2 H), 1.75 - 1.89 (m, 2 H), 1.50 - 1.57 (m, 3 H); 13C NMR (100 MHz ,CDCl3) δ 147.7, 
128.0, 126.7, 124.6, 124.2, 85.2, 79.0, 65.7, 65.4, 39.4, 39.2, 30.4, 29.6, 29.6, 27.5, 27.3; 
HRMS m/z calcd for C12H16O2 [(M+H)+]: 193.1229, found: 193.1223. 
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4-Methylocta-1,7-diene-4-ol (Table 9, Entry 4) 
 
The title compound was prepared using the general addition of Grignard to ketones 
procedure to afford a yellow oil (99%, 1.40 g). Rf 0.29 (20 v/v % EtOAc/hexanes); 1H NMR 
(CDCl3, 600MHz): δ 5.80 - 5.91 (m, 2 H), 5.09 - 5.20 (m, 2 H), 5.05 (d, J = 17.6 Hz, 1 H), 
4.96 (d, J = 10.5 Hz, 1 H), 2.25 (d, J = 6.4 Hz, 2 H), 2.12 - 2.19 (m, 2 H), 1.51 - 1.61 (m, 
3 H), 1.19 ppm (s, 3 H); 13C NMR (CDCl3, 101MHz): δ 139.2, 134.2, 119.1, 114.7, 72.4, 
46.7, 41.1, 28.6, 27.0 ppm; LRMS m/z calcd for C9H16O [M+] 140.1, found: 140.1. 
 
3-Methyl-1-phenylhept-6-en-1-yn-3-ol (Table 9, Entry 6) 
 
A 1 L round bottom flask was charged with phenylacetylene (4.39 mL, 40 mmol, 1 eq) in 
400 ml THF under argon.  The solution was cooled to -78 °C (CO2 (s)/acetone) and BuLi 
(24 mL, 48 mmol, 1.2 eq) was added.  The solution was stirred for 5 min.  Hex-5-en-2-one 
was added to the flask at -78 °C and warmed to rt.  The reaction was monitored by TLC 
(20 v/v % EtOAc:hexanes).  When starting material was consumed the reaction mixture 
was quenched with half saturated aqueous NH4Cl.  The aqueous layer was extracted with 
ethyl acetate (3 x 30 mL).  The combined organics were washed with brine, and dried over 
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anhydrous MgSO4.  The solution was filtered through a pad of celite and concentrated 
under reduced presure.  The resultant oil was purified by silica gel column chromatography 
(gradient 10:1 to 4:1 v/v % EtOAc:hexanes) to afford a clear colourless oil (71%, 5.71 g).  
Rf 0.40 (20 v/v % EtOAc/hexanes); 1H NMR (CDCl3, 600 MHz): δ 7.40 - 7.48 (m, 2 H), 
7.28 - 7.34 (m, 3 H), 5.85 - 5.99 (m, J = 16.9, 10.2, 6.7, 6.7 Hz, 1 H), 5.12 (d, J = 17.0 Hz, 
1 H), 5.02 (d, J = 11.7 Hz, 1 H), 2.31 - 2.47 (m, 2 H), 2.11 (br. s., 1 H), 1.81 - 1.92 (m, 2 
H), 1.61 ppm (s, 3 H); 13C NMR (CDCl3, 151MHz): δ 138.4, 131.6, 128.2, 122.7, 114.9, 
92.5, 83.7, 68.5, 42.7, 30.0, 29.3, 28.3 ppm; HRMS m/z calcd for C14H16O [(M-H)+] 
199.1123, found 199.1125. 
5-Phenylethynyltetrahydrofuran-2-methanol (Table 9, Entry 6) 
 
The title compound was prepared according to the general cyclization procedure to afford 
a light yellow oil (19%, 20.5 mg). Rf 0.21 (30 v/v % EtOAc/hexanes); 1H NMR (400MHz 
,CDCl3) δ 7.41 (dd, J = 3.3, 6.4 Hz, 2 H), 7.26 - 7.31 (m, 3 H), 4.22 - 4.38 (m, 1 H), 3.70 - 
3.81 (m, 1 H), 3.54 (dt, J = 5.4, 11.4 Hz, 1 H), 2.08 - 2.38 (m, 2 H), 1.80 - 1.93 (m, 2 H), 
1.64 (s, 3 H); 13C NMR (101MHz ,CDCl3) δ 131.7, 131.6, 128.2, 128.2, 91.9, 83.0, 80.7, 
79.2, 77.3, 77.2, 64.9, 41.0, 40.3, 28.0, 27.6, 27.1. 
3-Methyl-1-(trimethylsilyl)hept-6-en-1-yn-3-ol 
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The title compound was prepared as per the synthesis of compound 3-Methyl-1-
phenylhept-6-en-1-yn-3-ol (Table 9, Entry 6) to afford a clear colourless oil (39%, 168.5 
mg).    Rf 0.50 (20 v/v % EtOAc/hexanes);   1H NMR (CDCl3, 400MHz): δ 5.87 (dd, J = 
16.8, 10.2 Hz, 1 H), 5.06 (d, J = 17.2 Hz, 1 H), 4.97 (d, J = 10.2 Hz, 1 H), 2.18 - 2.34 (m, 
2 H), 1.97 (br. s., 1 H), 1.73 (ddd, J = 9.7, 6.5, 2.9 Hz, 2 H), 1.46 (s, 3 H), 0.15 ppm (s, 6 
H); 13C NMR (CDCl3, 101MHz): δ 138.4, 114.8, 109.2, 87.8, 68.3, 42.5, 29.9, 29.3, -0.1 
ppm;  HRMS m/z calcd for C11H20OSi [(M-H)+] 19.1205, found 195.1213. 
 
5-Methyltridec-1-en-5-ol 
 
 
The title compound was prepared by the general Grignard addition to ketones procedure to 
afford a yellow oil (83%, 2.1 g). Rf 0.82 (30 v/v % EtOAc/hexanes); 1H NMR (CDCl3, 
400MHz): δ 5.73 - 5.94 (m, 1 H), 5.03 (d, J = 17.2 Hz, 1 H), 4.94 (d, J = 10.2 Hz, 1 H), 
2.05 - 2.20 (m, 2 H), 1.51 - 1.58 (m, 2 H), 1.41 - 1.48 (m, 2 H), 1.24 - 1.34 (m, 14 H), 1.16 
(s, 3 H), 0.80 - 0.92 ppm (m, 3 H); 13C NMR (CDCl3,101MHz): δ 139.1, 114.3, 72.7, 42.0, 
40.8, 31.9, 30.2, 29.6, 29.3, 28.4, 26.9, 23.9, 22.7, 14.1 ppm; HRMS m/z calcd for 
C11H20OSi [M+] 212.2140, found 212.2136. 
(Z) -4-Methyl-1-phenylocta-1,7-diene-4-ol 
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A 10 mL round bottom flask was charged with 3-methyl-1-phenylhept-6-en-1-yn-3-ol (502 
mg, 2.5 mmol, 1 eq) in 3 mL of MeOH.  Quinoline (100 mg, 0.75mmol, 0.28 eq)  and 
Lindlar’s Catalyst (104.5 mg, 0.25 mmol, 0.1 eq.) were added to the solution.  H2 (g) was 
bubbled through the solution for 2 min and then placed under H2 using a balloon.  The 
reaction was monitored by TLC (20 v/v % EtOAc:hexanes).  When no alkyne was observed 
the reaction was filtered through a pad of celite and the solvent was removed by rotary 
evaporator.  The crude product was purified by silica gel column chromatography (10 % 
EtOAc:hexanes) to afford a pale yellow oil (35%, 175 mg)   Rf 0.47 (30 v/v % 
EtOAc/hexanes); 1H NMR (CDCl3, 600 MHz): δ 7.28 - 7.35 (m, 4 H), 7.22 - 7.25 (m, 1 
H), 6.52 (d, J = 12.9 Hz, 1 H), 5.77 - 5.85 (m, 1 H), 5.66 (d, J = 12.9 Hz, 1 H), 5.00 (d, 
J=17.0 Hz, 1 H), 4.93 (d, J=8.2 Hz, 1 H), 2.13 - 2.19 (m, 2 H), 1.62 - 1.68 (m, 2 H), 1.54 - 
1.58 (m, 1 H), 1.33 ppm (s, 3 H); 13C NMR (CDCl3,151 MHz): δ 138.8, 138.2, 137.4, 
128.8, 128.3, 128.1, 127.0, 114.4, 74.5, 42.7, 29.5, 28.6 ppm; HRMS m/z calcd for 
C11H20OSi [M+] 202.1358, found 202.1349. 
 
 
 
(E)-3-Methyl-1-phenylhepta-1,6-dien-3-ol 
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A 10 mL round bottom flask was charged with 3-Methyl-1-phenylhept-6-en-1-yn-3-ol 
(537.4 mg, 2.5 mmol, 1 eq) in 2 mL Ether.  The solution was cooled to 0 °C and added 
Red-Al (1.27 g, 4.1 mmol, 1.6 mL) dropwise as a solution in toluene.  The mixture was 
allowed to warm to rt and was monitored by TLC (20 v/v % EtOAc:hexanes).  When the 
reaction was complete by TLC it was quenched by addition of 1M H2SO4.  The aqueous 
layer was extracted with ether (3 x 5 mL).  The organic layers were combined and washed 
with brine and dried over MgSO4.  Solvent was removed under reduced pressure.  The 
crude product was purified via silica gel chromatography (10 v/v % EtOAc:hexanes) to 
afford a yellow oil (39%, 211.5 mg).   Rf 0.39 (20 v/v % EtOAc/hexanes); 1H NMR (CDCl3, 
400 MHz): δ 7.33 - 7.37 (m, 2 H), 7.29 (t, J = 7.6 Hz, 2 H), 7.15 - 7.24 (m, 1 H), 6.56 (d, 
J = 16.0 Hz, 1 H), 6.24 (dd, J = 16.0, 1.6 Hz, 1 H), 5.75 - 5.88 (m, 1 H), 4.96 - 5.06 (m, 1 
H), 4.93 (d, J = 10.2 Hz, 1 H), 2.08 - 2.18 (m, 2 H), 1.66 - 1.73 (m, 2 H), 1.55 (s, 1 H), 1.37 
ppm (d, J = 1.6 Hz, 3 H); 13C NMR (CDCl3,100 MHz): δ 138.8, 136.9, 136.4, 128.6, 127.4, 
127.3, 126.4, 114.6, 73.3, 41.7, 28.5, 28.4.;  HRMS m/z calcd for C11H20OSi [M+] 
202.1358, found 202.1351. 
 
 
 
1-(but-3-enyl)cyclohexanol (Table 9, Entry 10) 
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The title compound was prepared using the general addition of Grignards to ketones 
procedure to afford a clear colourless oil (69%, 798 mg).  Rf 0.83 (30 v/v % 
EtOAc/hexanes); 1H NMR (CDCl3 ,400 MHz): δ 5.78 - 5.91 (m, J = 17.0, 10.3, 6.6, 6.6 
Hz, 1 H), 5.03 (d, J = 17.2 Hz, 1 H), 4.94 (d, J = 10.2 Hz, 1 H), 2.08 - 2.18 (m, 2 H), 1.36 
- 1.64 (m, 13 H), 1.30 - 1.36 (m, 2 H), 1.18 - 1.30 ppm (m, 1 H); 13C NMR (CDCl3, 
101MHz): δ 139.3, 114.3, 71.4, 41.4, 37.5, 27.4, 25.8, 22.2 ppm; HRMS m/z calcd for 
C10H18O [M+] 154.1356, found 154.1358. 
Oxaspiro[4.5]decan-2-ylmethanol (Table 9, Entry 10) 
 
The title compound was prepared using the general cyclization procedure to afford a yellow 
oil (34%, 154.5 mg).  Rf 0.19 (30 v/v % EtOAc/hexanes); 1H NMR (CDCl3 ,400 MHz): δ 
4.02 - 4.13 (m, 1 H), 3.66 (dd, J = 11.3, 2.3 Hz, 1 H), 3.44 (dd, J = 11.1, 5.3 Hz, 1 H), 2.10 
(br. s., 1 H), 1.83 - 1.96 (m, 1 H), 1.59 - 1.81 (m, 5 H), 1.27 - 1.57 ppm (m, 8 H); 13C NMR 
(CDCl3, 101MHz): δ 78.1, 65.2, 38.3, 37.3, 27.1, 25.6, 24.0, 23.7 ppm; HRMS m/z calcd 
for C10H18O2 [M+]170.1307, found 170.1306. 
 
 
1-(but-3-enyl)cyclopentanol (Table 9, Entry 9) 
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The title compound was prepared using the general Grignard addition to ketones procedure 
to afford a light yellow oil (42%, 441.7 mg). Rf 0.66 (30 v/v % EtOAc/hexanes); 1H NMR 
(CDCl3, 400MHz): δ 5.76 - 5.99 (m, 1 H), 5.04 (d, J = 17.2 Hz, 1 H), 4.94 (d, J = 10.2 Hz, 
1 H), 2.12 - 2.26 (m, 2 H), 1.72 - 1.87 (m, 3 H), 1.47 - 1.72 (m, 10 H), 1.36 ppm (d, J = 2.3 
Hz, 2 H); 13C NMR (CDCl3 ,101MHz): δ 139.3, 114.3, 82.5, 40.5, 39.8, 29.3, 23.8 ppm; 
HRMS m/z calcd for C9H16O[M+]140.1203, found 140.1198. 
Oxaspiro[4.4]nonan-2-ylmethanol (Table 9, Entry 9) 
 
The title compound was prepared using the general cyclization procedure to afford a yellow 
oil (41%, 34.6 mg).  Rf 0.15 (30 v/v % EtOAc/hexanes); 1H NMR (CDCl3, 400 MHz): δ 
4.00 - 4.08 (m, 1 H), 3.66 (dd, J = 11.3, 3.1 Hz, 1 H), 3.46 (dd, J = 11.3, 5.5 Hz, 1 H), 1.87 
- 2.00 (m, 2 H), 1.65 - 1.85 (m, 8 H), 1.49 - 1.63 ppm (m, 4 H); 13C NMR (CDCl3, 
101MHz): δ 78.3, 65.4, 38.9, 38.1, 36.6, 27.6, 24.0 ppm;  
 
 
 
 
2,2,3-Trimethylhept-6-en-ol (Table 9, Entry 5) 
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The title compound was prepared using the general Grignard addition to ketones procedure 
to afford a yellow oil (84%, 943.1 mg).  Rf 0.50 (20 v/v % EtOAc/hexanes); 1H NMR 
(CDCl3, 400 MHz): δ 5.79 - 5.92 (m, 1 H), 5.04 (d, J = 17.2 Hz, 1 H), 4.94 (d, J = 10.2 Hz, 
1 H), 2.05 - 2.28 (m, 2 H), 1.46 - 1.68 (m, 2 H), 1.12 (s, 3 H), 0.93 ppm (d, J = 2.0 Hz, 9 
H); 13C NMR (CDCl3 ,101MHz): δ 139.6, 114.3, 76.3, 38.1, 35.2, 28.5, 25.3, 20.8 ppm 
LRMS m/z calcd for C10H20O [(M-CH3)+]141.1279, found 141.1. 
2-(4-methoxyphenyl)hex-5-en-2-ol 
 
The title compound was prepared using the general Grignard addition to ketones procedure 
to afford a light orange oil.  Rf 0.42 (30 v/v % EtOAc/hexanes); 1H NMR (CDCl3, 
400MHz): δ 7.30 - 7.37 (m, 2 H), 6.85 - 6.89 (m, 2 H), 5.71 - 5.85 (m, 1 H), 4.88 - 5.01 
(m, 2 H), 3.80 (s, 3 H), 1.85 - 2.06 (m, 4 H), 1.74 - 1.79 (m, 1 H), 1.54 ppm (s, 3 H); 13C 
NMR (CDCl3, 101MHz): δ 158.2, 139.9, 138.8, 125.9, 114.5, 113.4, 74.4, 55.2, 43.1, 30.3, 
28.6 ppm; HRMS m/z calcd for C13H18O2 [M+]206.1307, found 206.1313. 
 
 
 
5-Methylona-1,8-dien-5-ol (Table 9, Entry 3) 
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The title compound was prepared by the general Grignard addition to ketones procedure to 
afford a clear colourless oil (99%, 1.80 g). Rf 0.45 (20 v/v % EtOAc/hexanes); 1H NMR 
(CDCl3, 400MHz): δ 5.78 - 5.90 (m, 2 H), 5.04 (dd, J = 17.2, 1.6 Hz, 2 H), 4.95 (dd, J = 
10.2, 2.0 Hz, 2 H), 2.07 - 2.17 (m, 5 H), 1.52 - 1.59 (m, 5 H), 1.27 (s, 1 H), 1.18 ppm (s, 3 
H); 13C NMR (CDCl3, 101MHz): δ 138.9, 114.4, 72.6, 40.9, 28.3, 26.8 ppm; HRMS m/z 
calcd for C10H18O [M+]154.1358, found 154.1353. 
(5-(but-3-enyl)tetrahydrofuran-2-yl)methanol (Table 9, Entry 3) 
 
The title compound was prepared using the general cyclization procedure to afford a light 
yellow oil (55%, 43 mg). Rf 0.17 (30 v/v % EtOAc/hexanes); 1H NMR (600 MHz ,CDCl3) 
δ 5.83 (dd, J = 10.5, 17.0 Hz, 1 H), 5.02 (d, J = 17.6 Hz, 1 H), 4.93 (d, J = 9.9 Hz, 1 H), 
3.67 (d, J = 2.3 Hz, 1 H), 3.44 - 3.49 (m, 1 H), 2.05 - 2.15 (m, 2 H), 1.87 - 1.98 (m, 2 H), 
1.75 - 1.85 (m, 2 H), 1.67 - 1.75 (m, 1 H), 1.54 - 1.66 (m, 3 H), 1.19 - 1.32 (m, 3 H); 13C 
NMR (101 MHz CDCl3) δ 138.9, 114.1, 83.4, 79.1, 78.3, 65.3, 65.1, 40.9, 40.2, 37.1, 36.7. 
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Images of Co(modp)2 Column 
 
  
 Figure 17. The varying bands of decomposed cobalt catalyst (modp and piper ligands).   
Bands are clearly shown to elute at widely varying Rf values during column 
chromatography.  These bands in many cases overlap with the cyclized product and in 
several instances have been shown to make accurate characterization extremely difficult. 
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Spectral Data 
Spectra 1.  Ethyl-2-(4-methylpiperazin-1-yl)-2-oxoacetate (2.37) 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 2. Ethyl-2-(4-methylpiperazin-1-yl)-2-oxoactate (2.40) 
 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 3. 1-(tert-Butyldimethylsiloxy)hex-5-en-2-ol (2.41a) 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 4. 5-((tert-Butyldimethylsiloxymethyl)tetrahydrofuran-2-yl)methanol 
(2.42a) 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 5. (S)-(tert-Butyldimethylsilanyoxy)hept-6-en-3-ol (2.41b) 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 6. [(2R, 5R)-5-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-tetrahydrofuran-2-
yl]-methanol (2.42b) 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 7. 1-(tert-butyldimethylsilyloxy)-oct-7-en-4-ol (2.41c) 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 8. (5-(3-tert-Butyldimethylsilyloxy)propyl)tetrahydrofuran-2-yl)-methanol 
(2.42c) 
 
1H NMR (CDCl3, 400 MHz) 
103 
 
 
 
 
13C NMR (CDCl3, 100 MHz) 
104 
 
 
 
Spectra 9. 1-(Methoxymethyloxy)-oct-7-en-4-ol  
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 10. (5-(3-Methoxymethyoxy)propyltetrahydrofuran-2-yl)methanol 
(Table 7, Entry 1) 
 
1H NMR (CDCl3, 400 MHz) 
107 
 
 
 
 
13C NMR (CDCl3, 100 MHz) 
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Spectra 11. 1-(Benzoyloxy)-oct-7-en-ol  
 
1H NMR (CDCl3, 400 MHz) 
109 
 
 
 
 
13C NMR (CDCl3, 100 MHz) 
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Spectra 12. (5-(3-(Benzyloxy)propyl)tetrahydrofuran-2-yl) methanol 
(Table 7, Entry 2) 
 
1H NMR (CDCl3, 400 MHz) 
111 
 
 
 
 
13C NMR (CDCl3, 100 MHz) 
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Spectra 13. 1-(4-Methoxyphenyloxy)oct-7-en-4-ol 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 14. (5-(3-(4-Methoxyphenoxy)propyl)tetrahydrofuran-2-yl)-methanol 
(Table 7, Entry 3) 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 15. Nona-1,8-dien-5-ol 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 16. (5-(But-3-enyl)-tetrahydro-furan-2-yl)-methanol (Table 7, Entry 4) 
 
1H NMR (CDCl3, 400 MHz) 
119 
 
 
 
 
13C NMR (CDCl3, 100 MHz) 
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Spectra 17. 1-Phenyl-pent-4-en-ol 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 18. (5-Phenyl-tetrahydro-furan-2-yl)-methanol 
 (Table 7, Entry 6) 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 19. 1-Phenyl-hex-5-en-2-ol 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 150 MHz) 
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Spectra 20. (5-Benzyl-tetrahydro-furan-2-yl)-methanol (Table 7, Entry 7) 
1H NMR (CDCl3, 600 MHz) 
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Spectra 21. 1-Phenyl-hepta-1,6-dien-3-ol 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 22. (5-Styryl-tetrahydrofuran-2-yl)-methanol 
(Table 7, Entry 9) 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 23. (5-(but-3-enyl)tetrahydrofuran-2-yl)methanol 
(Table 9, Entry 3) 
 
 
1H NMR (CDCl3, 400 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 24. 4-Methylocta-1,7-diene-4-ol 
 
1H NMR (CDCl3, 600 MHz) 
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Spectra 25. 3-Methyl-1-phenylhept-6-en-1-yn-3-ol 
 
1H NMR (CDCl3, 600 MHz) 
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13C NMR (CDCl3, 100 MHz) 
 
 
136 
 
 
 
 
  
Spectra 26. 3-Methyl-1-(trimethylsilyl)hept-6-en-1-yn-3-ol 
 
1H NMR (CDCl3, 600 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 27. 5-Methyltridec-1-en-5-ol
 
 
1H NMR (CDCl3, 600 MHz) 
139 
 
 
 
 
 
 
 
13C NMR (CDCl3, 100 MHz) 
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Spectra 28. (E)-3-Methyl-1-phenylhepta-1,6-dien-3-ol
1H 
NMR (CDCl3, 600 MHz) 
 
  
141 
 
 
 
Spectra 29. (Z)-3-Methyl-1-phenylhepta-1,6-dien-3-ol
 
1H NMR (CDCl3, 600 MHz) 
 
 
142 
 
 
 
13C 
NMR (CDCl3, 100 MHz)  
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Spectra 30. 1-(but-3-enyl)-Cyclohexanol 
1H NMR (CDCl3, 600 MHz) 
144 
 
 
 
 
 
13C NMR (CDCl3, 100 MHz)  
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Spectra 31. 1-(but-3-enyl)-Cyclopentanol 
 
1H NMR (CDCl3, 600 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 32. 2,2,3-trimethylhept-6-en-3-ol 
 
1H NMR (CDCl3, 600 MHz) 
 
 
148 
 
 
 
 
 
 
13C NMR (CDCl3, 100 MHz) 
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Spectra 33. 1-oxaspiro[4.4]nonan-2-ylmethanol 
(Table 9, Entry 7) 
 
1H NMR (CDCl3, 600 MHz) 
 
 
150 
 
 
 
 
13C NMR (CDCl3, 100 MHz) 
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Spectra 34. 1-oxaspiro[4.5]decan-2-ylmethanol  
(Table 9, Entry 8) 
 
1H NMR (CDCl3, 600 MHz) 
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13C NMR (CDCl3, 100 MHz) 
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Spectra 35. (5-Phenyl-5-methyltetrahydrofuran-2-yl)methanol  
(Table 9, Entry 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (CDCl3, 600 MHz) 
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Spectra 36. 2-Phenylhex-5-en-2-ol 
 
 
1H NMR (CDCl3, 600 MHz) 
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Spectra 375-Phenylethynyltetrahydrofuran-2-methanol 
 (Table 9, Entry 6) 
 
 
 
1H NMR (CDCl3, 600 MHz) 
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Spectra 38. (5-(but-3-enyl)tetrahydrofuran-2-yl)methanol 
(Table 9, Entry 3) 
 
 
1
 H NMR (CDCl3, 600 MHz) 
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